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The bed nucleus of the stria terminalis (BNST) is currently widely studied due to its impact in the anxiety-, stress-, and fear-
related behaviours, as well as in addiction. The BNST is highly heterogeneous brain area constituting of set of subnuclei and a 
variety of neuron populations, properties of which have only partially been revealed by the earlier research. One of the neuron 
populations, on which only a very little research has been conducted, is the somatostatin (Sst) expressing neurons, highly abundant 
in the anterodorsal part of the BNST (adBNST), especially in oval and juxtacapsular nuclei of the BNST. This work aims to 
elucidate the connectivity of this Sst-neuron population, and their role in the behaviours related to BNST activation, particularly 
the anxiety-, reward-, and drug withdrawal-related behaviours. 
 
To specifically study the somatostatin neuron population in the adBNST, I targeted the neurons using stereotaxic delivery of 
AAV-vectors encoding a myristylated green fluorescent protein (GFP) for neuronal tracing to Sst-Cre-tdTomato reporter line 
mice (n=2), and Cre-inducible hM3Dq-DREADDs to Sst-IRES-Cre mice (n=21), with Cre-inducible mCherry fluorescent protein 
as a control (n=20). The mice were treated with activation-inducing 1.0 mg/kg i.p. clozapine-N-oxide (CNO) 30 min prior to the 
behavioural tests. To assess acute anxiety-like behaviour, I used the elevated-plus maze paradigm and a modified open field test, 
in which a novel object is introduced to the arena in the middle of the trial. To study the potential effect on reward-associated 
behaviours, I used the biased conditioned place preference (CPP) test, and for the withdrawal-linked behaviours, we used a method 
to precipitate the withdrawal symptoms with naltrexone in subchronically morphine-treated mice (n=9 hM3Dq, n=8 control). 
 
The neuronal tracing revealed that the adBNST Sst-neurons project to areas known to partake in stress and fear reactions as well 
as in autonomic and homeostatic control. Namely, projections were seen in medial and central amygdaloidal nuclei, lateral 
hypothalamus, periaqueductal grey, ventral pallidum, and parabrachial nucleus. In the elevated-plus maze, the CNO-induced 
activation of the Sst-neurons did not have any effect on the locomotor activity of the mice between the groups. At the same time, 
Sst activation did not seem to have any significant effect on the time the mice spent in the open arms, nor in the exploratory 
activities, like the frequency of the head dips or the stretch-attend postures. In line with these results, no effect on the movement 
between the groups was observed in the open field test. Similarly, no differences in anxiety-related behaviours, like in the time 
spent in the centre of the arena or in the number of contacts with the novel object during the last phase of the test, were observed. 
The CPP test failed to show any meaningful rewarding or aversive properties of CNO-induced activation of the Sst-neurons, while 
the movement rates of the groups during the conditioning trials were not different in statistically significant way. As for the 
withdrawal symptoms, all the mice showed the predetermined symptoms, but the test failed to show any differences between the 
study groups. 
 
The neuronal tracing revealed connectivity for the adBNST Sst-neurons with brain regions involved in fear- and anxiety 
behaviour, social encounters, and autonomic control. In spite of this, the CNO-induced chemogenetic activation of the adBNST 
Sst-neurons failed to show any significant behavioural effects in the chosen paradigms for anxiety-, and reward-related behaviours, 
and for withdrawal symptoms. Further research is needed to dissect the Sst-subcircuitry of adBNST, both in order to verify the 
observed output regions, and to elucidate the role these neurons play in modification of behavioural phenotypes. 
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Pääterihmaston tyvitumake (BNST; the bed nucleus of the stria terminalis) on ollut kasvavan tutkimuskiinnostuksen kohteena 
viimeisten kymmenen vuoden aikana, koska sen on havaittu olevan tärkeä keskushermoston tiedonkäsittelyn solmukohta, joka 
ohjailee ahdistukseen, stressiin ja pelkoon liittyvää käyttäytymistä. Sen on myös todettu olevan osa riippuvuudessa toimivaa 
hermoverkkoa. BNST on monimutkainen ja hyvin heterogeeninen aivoalue, joka koostuu useista eri alatumakkeista ja 
hermosolupopulaatioista. Yksi merkittävistä BNST:n hermosolupopulaatioista on somatostatiinia ilmentävät hermosolut, jotka 
ovat keskittyneet BNST:n anterodorsaalille alueelle, erityisesti ovaalitumakkeeseen ja juxtakapsulaaritumakkeeseen. Näiden 
hermosolujen ominaisuuksia ja toimintaa tunnetaan erityisen huonosti. Tämän työn tarkoituksena on kartoittaa BNST:n 
somatostatiini-hermosolupopulaation hermostollisia yhteyksiä, sekä selvittää niiden osuutta BNST:hen yhdistetyn käyttäytymisen 
muodostumisessa, erityisesti keskittyen ahdistus-, palkkio-, ja vieroitusoirekäyttäytymiseen. 
 
Hermosoluyhteyksien selvittämiseksi käytin AAV-vektorilla somatostatiini-tdTomato-reportterihiirilinjaan (n=2) siirrettyä cre-
riipuvaisesti myristyloitua vihreää fluorensoivaa proteiinia (GFP; green fluorescent protein). Käyttäytymisroolin selvittämiseksi 
somatostatiini-IRES-cre-hiirikantaan siirrettiin niin ikään AAV-vektorilla cre-riippuvaisesti hM3Dq-DREADD-reseptoreita 
(designer receptor exclusively activated by designer drug; n=21) ja mCherry-fluorensoivaa proteiinia sisältävää 
kontorllirakennetta (n=20). Hiirille annettiin intraperitoneaalisesti 1,0 mg/kg klotsapiini-N-oksidia (CNO) 30 minuuttia ennen 
jokaista käyttäytymiskoetta designerreseptorien aktivoimiseksi. Akuutin ahdistukäyttäytymisen arviomiseksi käytin kohotettua 
ristisokkeloa (elevated plus maze, EPM) sekä muunneltua avoimen kentän (open field, OF) koetta, jossa keske kokeen kentälle 
asetetaan uusi esine. Palkkiokäyttäytymistä arvioitiin paikkaehdollistumalla (conditioned place preference, CPP), ja 
vieroitusoireita mallinnettiin naltreksonilla nopeutettua morfiini-vieroituskoetta (vieroitusoireissa n=9 hM3Dq, n=8 kontrolli). 
 
Hermosolujen jäljestyskoe paljasti antreodorsaalin BNST:n somatostatiinisolujen viejähaarakkeiden kulkeutuvan aivoalueille, 
joiden tunnetaan olevan tekemisissä stressin, pelon ja sosiaalisten kanssakäymiseen liittyvien käyttäytymisten säätelyssä sekä 
autonomisten ja homeostaattisten toimintojen ohjailussa: fluorensoivia hermosäikeitä oli nähtävissä mantelitumakkeessa, 
hypotalamuksessa, periakveduktaalisessa harmaassa aineessa, ventraalisessa linssitumakkeessa sekä parabrakiaalisessa 
tumakkeessa. Käyttäytymiskokeiden osalta, DREADD-indusoitu somatostatiinineuronien aktivointi ei aiheuttanut näkyviä 
käyttäytymismuutoksia EPM- tai OF-kokeessa: ryhmien välillä ei ollut eroja liikeaktiivisuudessa, mutta ei myöskään ahdistukseen 
liitetyissä muuttujissa kuten ristisokkelon avoimissa haaroissa tai avoimen kentän keskiosassa vietetyssä ajassa. CPP-koe ei niin 
ikään paljastanut eroavaisuuksia ryhmien välillä. Morifiini-vieroituskokeessa kaikilla hiirillä havaittiin tyypilliset fyysiset 
vieroitusoireet, mutta eroja niiden määrissä tai kestoissa ei ryhmien välillä havaittu. 
 
Tämä pro gradu –tutkimus osoittaa alustavasti, että anterodorsaalisen BNST:n alueella sijaitsevat somatostatiinineuronit 
hermottavat tunnettuja ahdistus- ja pelkoreaktioita sekä elimistön autonomisia vasteita sääteleviä aivoalueita. Käyttäytymiskokeet 
eivät kuitenkaan kyenneet osoittamaan tämän solupopulaation kemogeneettisen aktivoinnin aiheuttavan käyttäytymismuutoksia 
valituissa kokeissa. Näin ollen tarvitaan jatkotutkimuksia kyseisen somatostatiinihermosolupopulaation ominaisuuksien 
selvittämiseksi.       
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aca anterior commisure 
adBNST   anterodorsal part of the bed nucleus of the stria terminalis 
BNST   the bed nucleus of the stria terminalis 
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IPAC interstitial nucleus of the posterior limb of the anterior commisure 
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MAPK   mitogen-activated protein kinase 
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MeA   medial nucleus of amygdala 
NAc   Nucleus accumbens 
nNOS neuronal nitric oxide synthase 
NPY   neuropeptide Y 
OCD obsessive compulsive disorder 
OF   open field 
ovBNST   oval nucleus of the bed nucleus of the stria terminalis 
p53 tumour protein 53 
PAG periaqueductal grey 
PBN parabrachial nucleus 
PFC   prefrontal cortex 
PTSD   post-traumatic stress disorder 
PV parvalbumin 
s.c.   subcutaneous (administration) 
SN   Substantia nigra 
Sst   somatostatin 
Sstr somtostatin receptor 
st   stria terminalis 
VP ventral pallidum 
VTA   ventral tegmental area 
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1 INTRODUCTION 
 
The bed nucleus of the stria terminalis (BNST) is a small brain area in the posterior 
forebrain, known to be part of the valence processing circuitry of the brain (Somerville et 
al. 2010; Kim et al. 2013; Calhoon and Tye 2015). The BNST has long been known to 
mediate stress-related, defensive, and social behaviours, but recent advances in genetic 
and neuron-controlling tools, such as optogenetics and transgenic animals, have brought 
forth new pieces of evidence of the BNST’s potential role in debilitating stress-related 
neuropsychiatric disorders, like generalized anxiety disorder, and addiction (Erb et al. 
2001; Kim et al. 2013). This has raised a new interest in researching the BNST in humans 
after several decades of retirement  (Avery et al. 2014; Straube et al. 2007). It is also an 
intriguing brain area with significant sexual dimorphism, which has gained the BNST 
some societal relevance through studies showing that the dimorphic characteristics are 
reversed in transgender people (Allen and Gorski 1990; Zhou et al. 1995). The BNST is 
regionally highly heterogeneous, and well known as a significant source of corticotrophin 
releasing factor (CRF) expressing neurons, which have been extensively studied for their 
role in initiating stress responses (Bota et al. 2012; Partridge et al. 2016). BNST also 
harbours a major group of somatostatin (Sst) expressing neurons. While the presence of 
these Sst-neurons has been known for years, virtually no research studying their neuronal 
actions or their role in regulation of behaviour has been published. 
 
This work will first review the current knowledge on both Sst and the BNST. While Sst 
is an important active substance working both in the central nervous system and elsewhere 
in the system, mainly being expressed in the gastrointestinal (GI) tract and the pancreas, 
the review will concentrate on its role in the central nervous system. The work will then 
continue to describe and discuss the experiments aiming to characterise the anatomical 
connectivity of Sst-neurons in the anterodorsal part of the BNST, and their role in 
neuropsychiatrically relevant behavioural phenotypes.        
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2 SOMATOSTATIN 
 
In 1972, Brazeau et al. discovered and purified a peptide substance that inhibits the 
secretion of growth hormone in sheep hypothalamus.  This hormone, today known as 
somatostatin (Sst, also SOM), is widely expressed in the mammalian system, being 
secreted as a hormone from the pituitary and the GI-tract, and expressed as a neuropeptide 
in neurons in the central nervous system (Guillemin 2008; Rai et al. 2015). It inhibits the 
release of gastric peptides and hormones in GI-tract and in pancreas. Synthetic analogues 
of Sst (such as octreotide, lantreotide, pasitreotide) are widely used as drugs to treat 
acromegaly, the state of excess secretion of growth hormone, but also in different kinds 
of neuroendocrine, and paracrine tumours. The exhaustive summary of somatostatin’s 
role throughout the body is not in the scope of this review, and therefore the following 
discussion is concentrated on Sst in the brain. 
2.1 Somatostatin and its receptors 
 
Sst is a cyclic polypeptide hormone synthesized as a larger prohormone, pre-
prosomatostatin (Wynick et al. 1989; Patel 1999). Through enzymatic cleavage from the 
C-terminal, the two bioactive forms of Sst are produced: the shorter, a 14 amino-acid-
long peptide with a disulphide bridge between the two cysteine residues (SS14), is the 
more abundant form in the nervous system, while the other, a 28 amino-acid-long 
congener of the shorter peptide, elongated from the N-terminal (SS28), is prevalent in the 
peripheral tissues. In this work, the word somatostatin and abbreviation Sst are used to 
describe collectively both active forms. In the nervous system, Sst is synthesized mainly 
in neurons, varying in their location and morphology, as described later, but also in a 
lesser extent in glial cells (Davidson and Gillies 1993; Liguz-Lecznar et al. 2016). In 
neurons, Sst is stored in dense-core vesicles that are trafficked widely into dendrites,  axon 
and neuron soma, and is released in response to high frequency repetitive action potentials  
(Baraban and Tallent 2004; Ludwig and Leng 2006; Zhang et al. 2010). The release is 
usually slower than that of the classical neurotransmitters, due to the larger size of the 
peptide. The duration of the action is also longer, since there are no specialized uptake 
mechanisms for Sst, and therefore the peptide remains in the extracellular space for longer 
periods. 
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Sst exhibits inhibitory effects, and is especially known to block secretion of several 
hormones and other substances (Theodoropoulou and Stalla 2013). Namely, it suppresses 
the secretion of (1) growth hormone (GH) and prolactin in the pituitary, (2) glucagon and 
insulin in the pancreas, (3) and several other peptides and hormones in the gastrointestinal 
tract and in the kidneys (Brazeau et al. 1973; Bloom et al. 1974; DeVane et al. 1974; 
Gomez-Pan et al. 1976). In the nervous system, Sst works as an inhibitory neuropeptide, 
causing hyperpolarisation and decreased neurotransmitter release in the target neurons  
(Viollet et al. 2008). Additionally, Sst is known to have antiproliferative effects, 
especially in tumour cells, by being able to arrest the cell cycle and to induce apoptosis  
(Cordelier et al. 1997; Thangaraju et al. 1999). Sst is known to be an evolutionarily 
conserved peptide throughout the vertebrates, making the translation of the results in 
animal studies into clinical applications more viable (Gahete et al. 2010). However, the 
interspecies similarity of the effects of Sst are difficult to predict due to differences in 
receptor types and signal cascades (Enjalbert et al. 1982; Giordano et al. 2007). 
 
The physiological actions of Sst are mediated through five structurally similar receptor 
proteins, known as Sstr1 to Sstr5, with differing expression patterns and distinct 
pharmacological properties (Table 1; Bruno et al. 1992; Patel 1999). All five receptors 
are G-protein coupled, and share some of the metabotropic signalling cascades, like the 
inhibition of adenylyl cyclase (AC), and modulation of mitogen-activated protein kinase 
(MAPK). The receptors also have subtype specific intracellular interaction pathways, 
making subtype-selective specialisation possible.  
 
The inhibition of secretory action is usually mediated through the inhibition of exocytosis, 
by Sst inhibiting AC and reducing the cyclic adenosine monophosphate (cAMP) 
formation (Figure 1;  (Heisler et al. 1982). The receptors are also linked with several 
subsets of K+ ion channels, through which they cause cell membrane hyperpolarisation  
(Wang et al. 1989; Sims et al. 1991). The hyperpolarisation also decreases Ca2+ inflow 
through the inhibition of voltage-sensitive Ca2+ channels. The cell cycle arrest is induced 
by the activation of MAPK, while the activation of tumour protein 53 (p53) triggers 
apoptosis, an effect mostly credited to Sstr3-linked pathways (Cordelier et al. 1997; 
Thangaraju et al. 1999; Theodoropoulou and Stalla 2013).   
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Table 1. Properties of somatostatin receptors. Both the intracellular effects, and the 
expression sites in the brain represent only the most major systems described in the 
literature, as comprehensive listing of all findings is outside of the scope of this review. 
Legend: ↑ increased activity/level, ↓ decreased activity/level, = no shown effect, blank 
denotes no knowledge. Adapted from Patel 1999; Liguz-Lecznar et al. 2016; 
Theodoropoulou and Stalla 2013.  
 
 
 Sstr1 Sstr2 Sstr3 Sstr4 Sstr5 
G-protein 
coupling 
Gi/o Gi/o Gq/11 Gi/o Gq/11 Gi/o Gi/o Gq/11 
Affinity 
for Sst14 
and Sst28 
14 = 28 14 = 28 14 = 28 14 = 28 14 < 28 
cAMP ↓ ↓ ↓ ↓ ↓ 
cGMP ↑ ↑   ↓ 
Adenylyl 
cyclase 
↓ ↓ ↓ ↓ ↓ 
K+ 
channels 
↑ ↑ ↑ ↑ ↑ 
Ca2+ 
channels 
↓ ↓ =  ↓ 
MAPK ↑ ↓/↑ ↑/↓ ↑ ↓ 
p53  ↑ ↑   
Major 
expression 
in the 
brain 
amygdala, 
cortex, 
hippocampus, 
hypothalamus 
amygdala, 
cortex, 
hippocampus, 
hypothalamus 
amygdala, 
cerebellum, 
hippocampus, 
olfactory 
bulb, striatum 
amygdala, 
cerebellum, 
hippocampus, 
olfactory 
bulb, striatum 
hypothalamus, 
preoptic area 
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2.2 Somatostatin in the central nervous system 
 
Somatostatin-expressing neurons (Sst-neurons) are widely distributed in the mammalian 
central nervous system, and are, for example, found in great abundance in the forebrain 
areas like cortex, hypothalamus, amygdala, and the extended amygdala structures, but 
also in the brainstem and the spinal cord (Giehl and Mestres 1995; Saha et al. 2002; 
Tomioka et al. 2005; Viollet et al. 2008). Being one of the main subclasses of the cortical 
interneurons, Sst-neurons have been a target for scientific interest for decades, revealing 
significant heterogeneity and variability in their properties between, and within, the brain 
structures. Even though it is true that most research on Sst in the brain is based on studies 
made with animal models (also applicable to most of the research referenced in the 
Figure 1. Some of the intracellular pathways in Sst-signalling. Sst inhibits adenylyl 
cyclase (AC), reducing the levels of cyclic AMP (cAMP), a widely active secondary 
messenger, also needed for induction of exocytosis. Sst can also activate the MAP 
kinase (MAPK) and tumour protein 53 (p53), which are linked to Sst-induced cell 
cycle arrest and apoptosis, respectively. Sst also activates several potassium channels, 
including the G protein-coupled inwardly-rectifying potassium channel (GIRK), 
which lead into membrane hyperpolarization through potassium (K+) outflow. 
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following), the expression of Sst and its receptors in humans is very similar with rodents  
(Reubi et al. 1986; Mengod et al. 1992). This is especially true in the cortex, the 
amygdaloidal structures, and the brainstem.  The following will outline properties of Sst-
neurons, brain regions with high expression of Sst-neurons, and discuss some of the 
known neuropsychiatric disorders linked with changes in the Sst-system. 
2.2.1 Somatostatin-expressing neurons 
 
Sst-neurons are a heterogeneous group of neurons, with varying electrophysiological, 
morphological, and neurotransmitter expression profiles (Liguz-Lecznar et al. 2016). Due 
to the diversity of the Sst-neurons, it might be problematic to treat them as a unitary group 
of neurons, and for that, several attempts on further classifying the Sst-neurons 
throughout the brain have been made (Wang et al. 2002; Ma et al. 2006; Sosulina et al. 
2006; McGarry et al. 2010). Sst-neurons are most often classified by either their 
electrophysiological or molecular properties. The electrophysiological profiles of the Sst-
neurons seem to vary, to some extent, between different brain regions. The majority of 
the cortical Sst-neurons show classical accommodating responses, but subsets of burst-
accommodating, non-accommodating, and irregular spiking Sst-neurons have also been 
identified (Wang et al. 2002; Wang et al. 2004). It has also been shown that in γ-
aminobutyric acid (GABA) releasing Sst-neurons, GABA and Sst release contribute to 
different kinds of postsynaptic signals (Tang and Augustine 2015). In study with 
claustrum Sst-neurons, the acute inhibitory postsynaptic currents were GABA-dependent, 
while Sst caused prolongation of action potential duration.  
 
Sst-neurons often co-express GABA, which is natural seeing the potential synergistic 
effects of two transmitters with inhibitory action (Viollet et al. 2008). Besides that, Sst-
neurons have been shown to have co-expression with several other neuropeptides, like 
corticotrophin releasing factor (CRF), neuropeptide Y (NPY), and neuronal nitric oxide 
synthase (nNOS), and with calcium-binding proteins, like parvalbumin (PV), calbindin, 
and calretinin. There are also data showing co-expression of Sst and dopamine in the 
hypothalamus, and of Sst and tyrosine hydroxylase, a commonly used marker for 
dopamine neurons, in the midbrain (Dulcis et al. 2013; Forss M, unpublished data 2017). 
Like with the electrophysiological profiles, the co-expression of Sst and other transmitters 
7 
 
and proteins varies greatly between the brain areas, and different subtypes seem to be 
typical for different anatomical regions: for example, in the rodent frontal and visual 
cortices, Sst- and calretinin have not been shown to overlap, whereas in sensorimotor 
cortex, 40 % of Sst-neurons were shown to co-express calretinin (Kubota et al. 1994; 
Halabisky et al. 2006). Seeing the high variety of co-expressing neuropeptides and 
transmitter, and the above-mentioned observation on Sst and transmitter being able to 
cause different kinds of postsynaptic signals, it would be imprudent to group all the 
neurons expressing Sst into one category. 
 
In the cortex, Sst is co-expressed with GABA in inhibitory neurons, constituting 20 – 30 % 
of all GABA neurons in the neocortex (Tomioka et al. 2005; Uematsu et al. 2008). Out 
of these, interneurons called Martinotti cells are the predominant cell type. They are 
mostly found on the layers 2/3 and 5, innervating the apical dendrites of the pyramidal 
neurons of the same cortical layers in the layer 1(Kawaguchi 1993; Ma et al. 2006). A 
smaller group of Sst-interneurons, known as the nest- and small-basket cells, has also 
been identified in the cortical layers 4 and 5. The Sst-interneurons actively participate in 
integration of sensory inputs, and in formation of synchronised oscillations together with 
PV-interneurons, and are implicated in experience-dependent and de novo neuronal 
plasticity, thus playing a role in reshaping neural networks  (Kuki et al. 2015; Scheyltjens 
and Arckens 2016; Tang et al. 2014). Some of the cortical Sst-neurons are also known to 
send projections to other cortical regions (cortico-cortical projections) and to the striatum 
(Tomioka et al. 2005; Rock et al. 2016) These neurons constitute only a small fraction of 
the cortical Sst-neurons, but have been shown to participate in control of behaviour: it 
was recently shown, that optogenetic modulation of the cortico-striatal Sst-neuron 
projection affected the locomotor activity of mice (Melzer et al. 2017).  
 
Like in the cortex, locally innervating and projecting Sst-neurons have been identified in 
the amygdala (Saha et al. 2002; Sosulina et al. 2006). The Sst-interneurons innervate the 
local principal neurons and other interneurons in a distal dendrite preferring manner, and 
are, in close co-operation with PV-interneurons, strongly involved in controlling fear 
related behaviours in rodents (Muller et al. 2007; Li et al. 2013; Wolff et al. 2014). The 
other subgroup of amygdala Sst-neurons are projection neurons, which form two distinct 
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projection systems. The first one emerges from the lateral amygdala, innervating 
hypothalamus, entorhinal cortex, and more locally the other amygdala nuclei, except for 
central nucleus (CeA; McDonald et al. 2012; McDonald and Zaric 2015). From the CeA 
originates the other Sst-projection system, sending outputs to the bed nucleus of the stria 
terminalis (BNST), and through it to the brainstem region, like the parabrachial nucleus 
(PBN) and the nucleus of solitary tract (Sosulina et al. 2006; Viollet et al. 2008). Also in 
the CeA, a set of predominantly Sst-expressing neurons sending projection to 
periaqueductal grey (PAG), and to paraventricular thalamic nucleus has been identified 
(Penzo et al. 2014). These GABAergic neurons are shown to be an important contributor 
to fear conditioning in mice, going through robust synaptic plasticity during the 
behavioural process.   
 
In addition to being a target for the amygdala Sst-projections, the BNST harbours in itself 
a significant population of Sst-neurons (Finley et al. 1981; Moga et al. 1989; Walter et al. 
1991; Nguyen et al. 2016). They are most concentrated in the oval and the juxtacapsular 
nuclei of the BNST, but also seen slightly scattered in the anteromedial and the 
anterolateral nuclei. These Sst-neurons are known to locally inhibit other neurons in the 
BNST, but apart from the projections to the PBN, no studies on their output profiles 
outside the BNST have been published (Moga et al. 1989; Magableh and Lundy 2014; 
Xu et al. 2016). 
 
One more major Sst-projecting systems is also found in the hypothalamus, more precisely 
in periventricular and paraventricular nuclei of hypothalamus (Dierickx and Vandesande 
1979). The Sst-neurons in hypothalamus project to the median eminence, affecting the 
pituitary cells through the capillaries of the portal vasculature, as well as to several parts 
of the limbic system and the midbrain areas, like the habenula, hippocampus, and 
substantia nigra (Viollet et al. 2008).  
2.2.2 Somatostatin in neuropsychiatric disorders 
 
Several studies have shown changes in Sst-system in a variety of neurological and 
neuropsychiatric disorders (Lin and Sibille 2013). The best known dysfunction of 
neuronal system with a link to Sst is acromegaly, the excess production of growth 
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hormone often caused by pituitary adenoma, to which Sst analogues have been the main 
clinical intervention for several years (Yen et al. 1974; Giustina et al. 2000). This 
endocrinological connection is well established, but the relationship between Sst and the 
several neuropsychiatric disorders remains elusive (Lin and Sibille 2013). 
 
As discussed earlier, high abundance of Sst-neuron is found in fear- and stress-related 
brain areas, the amygdala and the BNST (Sosulina et al. 2006). Therefore, it is not a 
surprise that Sst has been linked with stress- and anxiety-related behaviours (Kluge et al. 
2008; Albrecht et al. 2013). Direct infusions of Sst and its analogues to amygdala have 
been shown to exhibit anxiolytic effects, and the activation of Sst-system is known to 
cancel out the anxiogenic effects of CRF (Brown et al. 1984; Engin and Treit 2009; Yeung 
et al. 2011). Increased Sst release, and Sstr upregulation have also been reported in 
response to stressors, and the disinhibition of Sst-interneurons has been shown to result 
in anxiolysis (Nanda et al. 2008; Butler et al. 2012; Fuchs et al. 2016). These data, among 
others not mentioned here, suggest that Sst-signalling is inherently anxiolytic, and that 
the Sst-systems are recruited during the stress and in anxious states to antagonise the 
anxiogenic effects of the CRF-signalling. Interestingly, and contrarily to the 
aforementioned, a research showed that increased Sst release and increased Sstr2/4 : 
dopamine Drd2 –ratio on rat hypothalamic CRF-neurons increases anxiety-linked 
behaviour and the amounts of stress hormone corticosterone in the cerebrospinal fluid 
(CSF; Dulcis et al. 2013). This can still be, at least partly, explained by decreased 
inhibitory signalling on the CRF-neurons caused by the downregulation of the inhibitory 
Drd2-autoreceptors, but is still to show that the anxiolytic effect of Sst-release is not 
straightforward.  
 
Tripp et al. (2011) showed that the expressions of Sst and its pre-pro form are reduced in 
the anterior cingulate cortex in post mortem samples of human patients with major 
depressive disorder (MDD). Similar findings have been reported in different brain areas, 
like the prefrontal cortex (PFC), and the amygdala  (Sibille et al. 2011; Guilloux et al. 
2012). These findings match the results of earlier studies, showing decreased Sst-levels 
in the CSF during depressive episodes  (Agren and Lundqvist 1984; Molchan et al. 1993). 
Both, the Sst-system dysfunctions, and the occurrence of MDD, have been found to be 
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more prevalent in female patients in several cohorts, which has been used as an indirect 
proof for the relation of Sst and depressive disorders by some researchers (Sibille et al. 
2011; Tripp et al. 2011; Guilloux et al. 2012; Lin and Sibille 2013). 
    
Similar findings to MDD have been reported in patients with other neuropsychiatric 
disorders. In schizophrenia patients CSF Sst is also decreased, as is Sst-RNA expression 
in PFC (Reinikainen et al. 1990; Guillozet-Bongaarts et al. 2014). In addition, the number 
and density of Sst-neurons is reduced in hippocampus and entorhinal cortex (Konradi et 
al. 2011; Wang et al. 2011). Similar decreases in the Sst-neuron densities in the limbic 
systems, as well in Sst-RNA expression levels in PFC are seen in patients with bipolar 
disorder (Konradi et al. 2011; Sibille et al. 2011; Wang et al. 2011).  
 
One of the most constant Sst-related findings is the loss of Sst-interneurons in epilepsy  
(Sloviter 1987; Houser 2014). Several kinds of interneurons are shown to be affected, but 
the loss of, and the reorganisation of the remaining Sst-interneurons in the dentate gyrus 
are recurrently reported in the epileptic patients, and shown to be true in the most of the 
models of epilepsy as well (de Lanerolle et al. 1989; Robbins et al. 1991; Peng et al. 2013; 
Houser 2014). The reasons behind the Sst-interneuron selectivity are not yet known, but 
the findings have lead into some trials investigating Sst and its analogues as 
anticonvulsant medications, with some promising preclinical results (Vezzani et al. 1991; 
Kozhemyakin et al. 2013). 
 
Changes in the Sst-system like the ones described in the cases of neuropsychiatric 
disorders have been demonstrated also in neurodegenerative diseases (Lin and Sibille 
2013). In Alzheimer’s disease, a strong correlation between the changes in Sst-system 
and cognitive capabilities of the patients have been shown (Epelbaum et al. 2009). In 
Alzheimer’s disease patients, Sst-RNA expression and immunoreactivity is decreased, 
especially in the hippocampus, and widely in cortex (Davies et al. 1980; Candy et al. 1985; 
Dournaud et al. 1994).  Moreover, the CSF Sst-levels have been shown to be decreased, 
both in Alzheimer’s disease and in Parkinson’s disease patients with dementia  (Beal et 
al. 1986; Bissette et al. 1986). Recent studies have also investigated the role of Sstrs in 
downregulated Sst-signalling, finding that the hypermethylation of Sstr4 did not correlate 
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with the progression or symptomatology of the Alzheimer’s disease, but implicating the 
loss of Sstr2 function in the dysfunction of noradrenergic system in the Alzheimer’s 
disease (Grosser et al. 2014; Adori et al. 2015).  
 
To sum up, it has been shown that Sst retains, to some extent, anxiolytic and 
anticonvulsant properties (Brown et al. 1984; Tallent and Qiu 2008; Kozhemyakin et al. 
2013). Sst has also been implicated in several neuropsychiatric disorders (Table 2). While 
it is true that the evidence on the correlation of Sst-related deficits and the 
neuropsychiatric disorders keeps cumulating, and the research papers showing the 
correlation are readily cited, it remains questionable, if the Sst-system itself is the cause 
behind the disorders. Because Sst is widely expressed in neurons throughout the brain, 
and the Sst-neurons constitute almost roughly one third of the cortical interneurons, the 
decreases in the Sst-levels could be only a secondary biomarker of wider deficiencies in: 
for example, disturbances in the development of all cortical interneurons – known to be 
present in schizophrenia – would certainly affect also the Sst-interneurons, which in turn 
could lead into decreased Sst-RNA expression, as well as in lower Sst-levels in CSF (Volk 
and Lewis 2014). While the evidence on the correlation is undeniable, there is still room 
for further exploration to elucidate the role of Sst in neuropsychiatric disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
Table 2. Neuropsychiatric conditions where changes in Sst-system are implicated. 
Disorder Findings Reference 
Anxiety Amygdala infusion of Sst 
reduces anxiety 
 
Sst ↑ Sstr ↑ in stress  
 
 
 Butler et al. 2012  
 
 
Engin and Treit 2009;  
Nanda et al. 2008 
 
Mania CSF Sst ↑ 
 
 Sharma et al. 1995 
OCD CSF Sst ↑ 
 
 Altemus et al. 1993  
PTSD CSF Sst ↑ 
CSF Sst = 
 
Bremner et al. 1997  
Sautter et al. 200) 
 
Depression CSF Sst ↓ 
 
Sst expression ↓ 
- prefrontal cortex 
- cingulate cortex 
- amygdala  
 
Agren and Lundqvist 1984  
 
 
Sibille et al. 2011 
Tripp et al. 2011  
Guilloux et al. 2012 
 
Schizophrenia CSF Sst ↓ 
 
Sst-RNA ↓ in  
- prefrontal cortex 
 
Sst-neuron ↓ in 
- hippocampus 
- entorhinal cortex  
Reinikainen et al. 1990  
 
 
Guillozet-Bongaarts et al. 2014  
 
 
Konradi et al. 2010  
Wang et al. 2011 
Bipolar disorder Sst-RNA ↓ in  
- prefrontal cortex 
 
Sst-neuron ↓ in 
- hippocampus 
 
Sibille et al. 2011  
 
 
Konradi et al. 2010 
Epilepsy Sst-neurons ↓ 
- hippocampus 
 
Sst-neuron reorganisation 
- hippocampus 
 
 
de Lanerolle et al. 1989  
 
 
de Lanerolle et al. 1989 
Alzheimer’s disease CSF Sst ↓ 
 
Sst-RNA ↓ 
- cortex 
- hippocampus 
 
Bissette et al. 1986  
 
 
Candy et al. 1985  
Dournaud et al. 1994) 
Parkinson’s disease CSF Sst ↓ 
 
Beal et al. 1986  
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3 THE BED NUCLEUS OF THE STRIA TERMINALIS 
 
As mentioned earlier, the most significant Sst-neuron populations apart from the cortical 
interneurons have been observed in the hypothalamus, in the amygdala, and in the so 
called extended amygdala structures (Moga et al. 1989; Saha et al. 2002; McDonald et al. 
2012). The extended amygdala is a concept of a loop-like brain structure connecting the 
CeA and the medial nucleus of the amygdala (MeA), and the bed nucleus of the stria 
terminalis (BNST; Heimer 2003). The BNST has been a target of expansive interest in 
neuroscience field for several decades, and increasingly so during the last ten years due 
to its observed relevance in human stress-related psychiatric disorders, and the 
development of new technologies to study the BNST in detail (Lebow and Chen 2016). 
The BNST is a small forebrain structure, uniquely located as a connective hub between 
the cortical and the subcortical structures, integrating sensory, memory- and affection-
related information as a part of the valence processing circuitry (Calhoon and Tye 2015). 
It is an important structure in stress-related, social, defensive, and reproductive 
behaviours. This is also reflected in heterogeneous receptor expression in the BNST 
(Figure 4), indicating a wide variety in the nature of the neuronal inputs. The following 
chapter outlines the anatomy and connectivity of the rodent BNST, introduces the human 
BNST together with some translational aspects, and discusses some of the known 
behavioural roles of the brain region. 
3.2 The anatomy and the connectivity of the rodent BNST 
 
In rodents, the BNST is situated ventral to the septal nuclei and the lateral ventricles, 
occupying a small area dorsal and ventral to the anterior commissure, and ventromedial 
to the striatum, next to the internal capsule (Figure 2; Lebow and Chen 2016). Thus, it is 
perfectly positioned for its role of an information integrator: the BNST receives various 
inputs from cortical areas and the olfactory bulb, relaying sensory information, from the 
limbic system, such as the amygdala and the hippocampus, and from the midbrain areas 
related to reward, social interactions and stress control, like the VTA, the raphe nuclei, 
and the locus coeruleus. The BNST then sends information back to these structures to 
form a feed-back loop, but has also large outputs to brain areas controlling homeostasis, 
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such as the hypothalamus, the septal nuclei, the nucleus of the solitary tract, and the 
parabrachial nucleus (PBN).   
 
In rodents, the BNST is divided into several subdomains, the number of which vary 
between 12 and 18, depending on the author. This work is based on widely-accepted 
division of Bota et al. (2012), where 12 distinct regions with differing connectivity and 
chemoarchitectural properties are acknowledged. The common main division of the 
BNST is into its anterior and posterior parts. The anterior BNST includes the anterolateral, 
anteromedial, oval, fusiform, juxtacapsular, rhomboid, dorsomedial, ventral and 
magnocellular nuclei, while the posterior part is divided into only three subregions, the 
principal, intrafascicular, and transverse nuclei. 
 
The oval nucleus of BNST is, as the name implies, an oval shaped area between the 
internal capsule and the lateral ventricle, dorsal to the anterior commissure  (Dong et al. 
2001; Bota et al. 2012). It receives projections from the amygdala, especially from the 
CeA, dopaminergic projections from the VTA, noradrenergic projections from the locus 
coeruleus, and is known to be innervated by serotonin- and dopamine-neurons from the 
dorsal raphe nuclei  (Dong et al. 2001; Marcinkiewcz et al. 2016). Its GABAergic neurons 
are known to densely innervate locally, especially the neighbouring anterolateral and 
anteromedial nuclei of the BNST (Larriva-Sahd 2006; Jennings et al. 2013; Kim et al. 
2013; Turesson et al. 2013). Also, several kinds of neurons projecting to the amygdala, 
VTA, hypothalamus, and PBN have been identified. Of the BNST nuclei, it is in the oval 
BNST where the most abundant expression of Sst-neurons is observable (Figures 3 and 
7; Moga et al. 1989; Bota et al. 2012). Some of these Sst-neurons are shown to project to 
the PBN (Moga et al. 1989; Magableh and Lundy 2014).  
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Figure 2. Subdivisions and the main connections of the rodent BNST. A. The most 
anterior region of BNST consists of anteromedial (am, blue), anterolateral (al, red), 
oval (ov, yellow), juxtacapsular (ju, green), and fusiform nuclei (fu, purple). B. Still 
considered as part of the anterior BNST, the medial-most part of the BNST includes 
the dorsomedial (dm, green), rhomboid (rh, yellow), magnocellular (mg, red), and 
ventral nuclei (v, red). C. The posterior BNST consists of of principle (pr, green), 
interfascicular (if, red), and transverse nuclei (rh, blue). The schematic also details the 
main input and output connections of each of the three areas. The connectivity of the 
rodent BNST has been broadly described by Dong and Swanson in a series of papers 
using Phaseolus vulgaris-leucoagglutinin neuronal tracing method, reviewed by Bota 
et al. 2012; Lebow and Chen 2016.  Amy – amygdala, DR – dorsal raphe, FC – frontal 
cortex, Hyp – hypothalamus, LC – locus coeruleus, OB – olfactory bulb,VS – ventral 
subiculum, VTA – ventral tegmental area. 
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The anterolateral BNST, situated ventral to the oval nucleus, is a large integrative hub of 
many neuronal outputs and inputs, and heavily innervating the adjacent BNST nuclei 
(Dong and Swanson 2004a). It receives serotonergic projection from the dorsal raphe, 
and is connected to the hypothalamic-pituitary-adrenal (HPA) axis negative feedback 
loop by its outputs to the paraventricular hypothalamus, and by glutamatergic inputs from 
the ventral subiculum. It is also connected to the autonomic control system through the 
outputs to the ventral amygdala, the periaqueductal grey (PAG), and the PBN, as well as 
to the somatomotor system with connections to the VTA, the nucleus accumbens (NAc), 
and the substantia innominata.  
 
Figure 3. Subpopulations of neuropeptides and transporter proteins in the BNST. 
BNST is known to be largely GABAergic, but it expresses wide variety of 
neuropeptides. The heatmap is adapted from collated in situ hybridisation and 
immunostaining data by  Moga et al. 1989; Bota et al. 2012; Lebow and Chen 2016.  
 
Legend: al – anterolateral BNST, AII – angiotensin I, am – anteromedial BNST,  GAD65 – glutamate 
decarboxylase 65, GAD67 – glutamate decarboxylase 67, CCK – cholecystokinin, CRF – corticotrophin releasing 
factor, dm – dorsomedial BNST, DYN – dynorphin, ENK – encephalin, fu – fusiform BNST,  if – interfascicular 
BNST, ju – juxtacapsular BNST, mg – magnocellular BNST,  NPY – neuropeptide Y, NT – neurotensin, ov – oval 
BNST, pr – principle BNST, rh – rhomboid BNST, Sst – somatostatin, tr –transverse BNST, v – ventral BNST, 
VIP – vasoactive intestinal peptide, VGLUT1 – vesicular glutamate transporter 1, VGLUT2 – vesicular glutamate 
transporter 2, VGLUT3 – vesicular glutamate transporter 3.  
AII Strong
CCK Moderate
CRF Weak
DYN No data
ENK
NPY
NT
Sst
VIP
GAD65
GAD67
VGLUT1
VGLUT2
VGLUT3
al am o
v
ju rh d
m
fu v m
g
p
r
if tr
anterior posterior
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Despite their distinct locations, the juxtacapsular and the fusiform nuclei of the BNST 
have been shown to largely innervate the same neural systems  (Dong et al. 2000; Dong 
et al. 2001; Larriva-Sahd 2004). The neurons from the fusiform nucleus, located ventral 
to the anterior commissure, project to the CeA, the PVN, the NAc, and the PAG, while 
the juxtacapsular nucleus, situated right next to the internal capsule, ventral to the oval 
BNST, sends projections to the CeA and the basolateral amygdala (BLA), substantia 
Legend: α1 Adr – α1 adrenergic 
receptor, α2 Adr – α2 adrenergic 
receptor, α2-1 GABA – GABA-A α2 
receptor, α3-1 GABA – GABA-A α3 
receptor, al – anterolateral BNST, am 
– anteromedial BNST, AR – androgen 
receptor, β1 Adr – β1 adrenergic 
receptor, β2 Adr – β2 adrenergic 
receptor, β1-1 GABA – GABA-A β1 
receptor, β3-1 GABA – GABA-A β3 
receptor, γ1-1 GABA – GABA-A γ1 
receptor, CRFR1 – corticotrophin 
receptor 1, CRFR2 – corticotrophin 
receptor 2, D1 – dopamine receptor 1, 
D2 – dopamine receptor 2, dm – 
dorsomedial BNST, DOR – delta 
opioid receptor, ER – estrogen 
receptor, fu – fusiform BNST, GluR5 
– glutamate kainate receptors, GluR7 
– glutamate kainate receptor, HtR1a – 
serotonin receptor 1a, if – 
interfascicular BNST, ju – 
juxtacapsular BNST, KOR – kappa 
opioid receptor, mg – magnocellular 
BNST, mGluR2 – metabotropic 
glutamate receptor 2, mGlurR7A – 
metabotropic glutamate receptor 7A, 
mGlur7B – metabotropic glutamate 
receptor 7B, MOR – mu opioid 
receptor, NK3 – tachykinin receptor 
3,  ov – oval BNST, pr – principle 
BNST, rh – rhomboid BNST, tr –
transverse BNST, v – ventral BNST 
Figure 4. Subtypes of receptors in the BNST. The expression of receptors indicates, 
to some extent, the types of innervation BNST receives, either from the other BNST 
nuclei, or from the other brain areas. The heatmap is adapted from collated in situ 
hybridisation and immunostaining data by Bota et al. 2012; Lebow and Chen 2016.  
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nigra, and the dorsal raphe. The juxtacapsular BNST has also been shown to harbour a 
significant population of Sst-neurons (Moga et al. 1989). 
 
The medial regions of the BNST harbour significant connections to the hypothalamus: 
the anteromedial nucleus has direct contacts to the paraventricular nucleus of the 
hypothalamus (PVN), while the dorsolateral BNST has been shown to have wide 
connectivity with the whole hypothalamus  (Dong and Swanson 2006a; Dong and 
Swanson 2006b). In addition to the hypothalamus, the anteromedial BNST is connected 
with other homeostasis and autonomic control areas, like the vagal projections and the 
brainstem. On the other hand, the dorsomedial nucleus receives many inputs from several 
amygdala nuclei, the hippocampus and the frontal cortical regions, indicating a role more 
in the stress- and fear-related behaviours. 
 
The posterior BNST nuclei together receive major inputs from the amygdala, especially 
the MeA and CeA ( (Dong and Swanson 2004b). They send outputs back to the MeA, 
and are also strongly connected with the hypothalamic and the mesolimbic structures 
associated with social and reproductive behaviours, like the septal nuclei, hypothalamus, 
VTA and pallidum. Reflecting the reproductive behaviour-linked connections, the 
posterior BNST nuclei have rich expression of androgen and estrogen receptors (Hines et 
al. 1992; Campi et al. 2013; Janitzky et al. 2014). This is in line with the observations 
showing that the posterior part of the BNST is most prone to sexually dichotomous 
changes (Laflamme et al. 1998). In addition to the oval and the juxtacapsular BNST, the 
transverse nucleus in the posterior BNST seems to contain a group of Sst-neurons near 
the internal capsule  (Moga et al. 1989)  
3.2 The human BNST and translational aspects 
 
The human BNST is situated in the ventral forebrain, roughly at the level of the anterior 
commissure, bordered by the internal capsule and the lateral septal nuclei  (Walter et al. 
1991; Lebow and Chen 2016). It can be separated into three different subdivisions: lateral, 
central, and medial. The divisions are grouped together on the dorsal side of the anterior 
commissure (Figure 5A). Part of the BNST can be seen ventral to the commissure, and is 
therefore at times called the ventral subdivision. Declaring this naming invalid, 
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histological evidence show that the region is indistinguishable from the central division, 
and therefore the ventral division is most likely not its own subregion (Walter et al. 1991). 
 
The lateral division of the BNST is situated next to the internal capsule  (Walter et al. 
1991). The subdivision has typically a high occurrence of neuropeptide Y (NPY) 
expressing neurons and dense patterns of NPY-positive neuronal fibres. Also, fibres with 
substance P and synaptophysin immunoreactivity are often observed, but very few, or no 
neurons or varicosities expressing Sst or neurotensin (NT). Contrary to the lateral division, 
the central part of the BNST is characterised by strong Sst-immunoreactivity, both in the 
somas and in the neuronal fibres. Other extensively observed neuropeptides are 
enkephalin, and NT, with moderate innervation of vasoactive intestinal peptide (VIP) 
positive fibres. The medial BNST shows mostly strong substance P and NPY positive 
nerve fibres, in addition to moderate presence of Sst and enkephalin. Interestingly, Walter 
et al. reported that the neurons in the medial subdivision did not have immunoreactivity 
with any of the major neuropeptides they used in their study. The described 
immunohistochemical properties are summarized in Figure 5B. 
 
In humans, three distinct connective pathways in the BNST have been identified  (Krüger 
et al. 2015). The posterior bundle connects the BNST with the lateral amygdala and the 
cortical regions of the temporal lobe, by following the stria terminalis around the 
thalamus, while the ventral bundle follows the ansa peduncularis around the internal 
capsule to connect with the MeA and hypothalamus. Anterior pathway runs through the 
NAc and caudate nucleus to the prefrontal and the orbitofrontal cortices. While these three 
bundles are shown to be constant across individuals, there are many known brain areas 
connected with the BNST without consistent pathways observable with modern imaging 
tools  (Avery et al. 2014; Krüger et al. 2015; Torrisi et al. 2017). These areas include the 
thalamus, the pallidum, the hippocampus, the habenula, and especially the brainstem 
structures. Because the structural connectivity studies in human are largely based on the 
use of magnetic resonance imaging (MRI), there are limitations to the level of acquired 
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spatial resolution. This means, e.g. in the case of the BNST, that the origins of the three 
pathway bundles are not known at the level of subdivisions. The recent functional MRI 
(fMRI) studies have revealed functional connectivity between the BNST and most of the 
regions structurally connected with it, including the amygdala, several regions of the basal 
ganglia, like the NAc, and putamen, as well as the hippocampus and thalamus  (Avery et 
al. 2014). 
 
The BNST is an intriguing brain region in that it has been, several times, shown to be 
sexually dimorphic  (Allen and Gorski 1990; Zhou et al. 1995). The size of the BNST 
varies, being even as much as 2.5-times larger in males than in females. Giving this 
Figure 5. Anatomy, connectivity and chemoarchitecture of the human BNST. A. The 
human BNST is formed from three distinct subdivisions, medial, central, and lateral 
division (med, green; cent, red; lat, blue; respectively). Neuronal tracing studies, 
together with the use of fMRI technique, have revealed some of the functional and 
structural connections of human BNST, the most consistent findings of which are 
presented here. B. Heatmap of the expressions of different neuronal markers in the 
human BNST studied with immunohistochemistry, as described in Walter et al. 1991. 
CAB – calbindin, CHR-A – chromogranin-A, ENK – enkephalin, FAL – fucosylacetyl 
lactosamine, GFAP – glial fibrillary acid, MBP – myelin basic protein, NPH – 
neurophysin, NPY – neuropeptide Y, NT – neurotensin, SP – substance P, Sst – 
somatostatin, SYN – synaptophysin, VIP – vasoactive intestinal peptide.  
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finding social impact, Zhou et al. (1995) showed that the size differences are observable 
in transgender people, the BNST being smaller in female-identifying males than in male-
identifying males, and vice versa. Avery et al. (2014) also showed sexually differing 
BNST connectivity between the male and female test subjects; for example, 76 % of the 
structurally connected brain regions showed greater connectivity in females than in male 
participants. While this finding seems initially intriguing and plausible, the authors note 
that the observed differences in the connectivity may rise from methodological limitations, 
and that further verification is needed.       
 
From the translational research point of view, it is interesting to notice that the 
connections of the human BNST, both the structural and the functional, highly resemble 
the ones observed in rodents and non-human primates, implying at least some levels of 
evolutionary conservation of the structure across species  (Dong and Swanson 2004a;  
Dong and Swanson 2004b; Oler et al. 2012). Similarly, as has been discussed, the human 
and rodent BNST share some histological characteristics, namely expressing largely the 
same neuropeptides  (Moga et al. 1989; Walter et al. 1991). Despite the similarities, very 
little is, in fact, still known about the human BNST. For example, in humans, the BNST 
is proportionally larger than in rodents, indicating possible differences in the BNST 
circuitry  (Lesur et al. 1989; Avery et al. 2014). Because of these points, and since the 
BNST is likely to become increasingly more interesting site as a drug target, more 
research in the human BNST is needed, in addition to more comparative approach in 
animal research concerning the BNST function.  
3.3 Functional roles of the BNST  
 
The BNST is often considered to be an integrative hub responsible for valence monitoring 
(Lebow and Chen 2016). In other words, the BNST receives sensory information from 
the cortex, as well as memory and emotion related inputs from the limbic system, and in 
the BNST these streams of information are integrated to produce either positive 
(rewarding, appetitive, pleasant) or negative (aversive) valence to inherently neutral 
external stimuli (Calhoon and Tye 2015). From the BNST the integrated information is 
sent back to the input areas in cortical and limbic systems as a feedback, but also to brain 
areas controlling physiological and homeostatic states, enabling proper response to 
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external environment or setting. Valence surveillance is therefore important in every form 
of behaviour, making decision on the reasonable action possible. The BNST – together 
with amygdala – is the main link in this neuronal circuitry. Therefore, disruptions in this 
link could cause disturbances in mood and stress processing, and reflecting this, the 
BNST has been implicated in some psychopathological states. The following will shortly 
review the known role of the BNST in both healthy stress and social behaviour, and in 
some behavioural disorders.   
3.3.1 Stress 
 
Biological stress is the physiological reaction and adaptation to external stressors, such 
as a real or an anticipated environmental or homeostatic challenge, or a threat to the well-
being  (Ulrich-Lai and Herman 2009; Stephens and Wand 2012). This adaptation is of 
major importance for the survival of an organism. The physiological changes are 
mediated by the central nervous system through the modulation of the HPA axis and the 
autonomic nervous system. These two systems are responsible for the changes in heart 
and respiratory rates, and in the blood pressure, to name a few. The BNST is indirectly 
connected to both of these systems through its output regions, especially the HPA axis-
controlling hypothalamus, and the brainstem areas, like the PBN, and the nucleus of the 
solitary tract, responsible for the control of autonomic reactions  (Magableh and Lundy 
2014; Sosulina et al. 2006). Arguing for the role of the BNST, studies have shown that 
lesions in the anterior BNST decrease the HPA axis activation, while lesions in the 
posterior BNST contrarily increase it (Gray et al. 1993; Choi et al. 2007). Interestingly, 
also the size of the BNST has been shown to increase after chronic stress in rats, caused 
by the changes in dendritic arborisation (Vyas et al. 2003).  
 
Some researchers link the BNST to stress-control solely because of its connections with 
the other brain regions known to be affected in stress: noradrenergic input from the locus 
coeruleus is often implicated in stress together with other adrenergic signalling, as are the 
raphe nuclei, also relevant in arousal, and the ventral subiculum, which is considered to 
inhibit the HPA axis  (Andres et al. 1999; O'Mara 2005). While the exact role of the 
BNST in stress regulation is unknown, the different outputs and subregions are shown to 
act in separate parts of stress reactions, and even in opposing ways: Kim et al. (2013) 
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showed that optogenetic activation of oval BNST caused anxiogenic behaviours, whereas 
the activation of anterodorsal BNST (including roughly the anteromedial and the 
anterolateral BNST) was anxiolytic in nature. The same study also showed, that different 
outputs mediate different aspects of the behaviours, as the activation of the projections to 
lateral hypothalamus affected the open space avoidance (indicator of anxiety-like 
behaviour), but not the respiratory rate, while the opposite was true for the activation of 
the projections to the PBN. This shows that the BNST is not to be interpreted as one 
homogeneous brain region working as a filter, but as a multifunctional, and highly 
heterogeneous complex.      
3.3.2 Social behaviour 
 
Seeing that a negative social interaction can lead to physical threat, and a positive 
interaction could be an outset for reproduction, it is understandable that valence 
surveillance is tightly connected also to social encounters. Social behaviour network is 
known to consist of such nodes as the MeA, VTA, and hypothalamus (Newman 1999; 
Goodson and Kabelik 2009). The BNST is connected to this network again as a hub: parts 
of the BNST are known to connect to brain areas regulating aggression, defensive 
behaviour, mating and parental care, most important of which is the MeA, known to be 
important in both social recognition and social memory (Coria-Avila et al. 2014). 
Together these two brain regions, the BNST and MeA, have been shown to mediate 
partner preference and copulation behaviour, while aggressive behaviours are in part 
modulated by the vasopressin-androgen-projections from the BNST to the septal nuclei 
(Trainor et al. 2006; Coria-Avila et al. 2014). Data from Trainor et al (2006) indicates 
that estrogen-mediated activation of the BNST regulates the MeA activity, as they 
showed that c-Fos activation in the MeA after an aggressive encounter in mice positively 
correlated with estrogen receptor immunoreactivity in the BNST. The BNST is also 
connected with the habenula, a multifunctional set of nuclei, well known to be a mediator 
in sexual behaviours in rats (Rodgers and Law 1967; Modianos et al. 1975). Recently, a 
study showed that chronic social defeat, a model of psychosocial stress, increases ΔFosB 
expression in the BNST, indicator of repeated neuronal activation (Laine et al. 2017). The 
same study also showed increased BNST-activation, observed with MRI, in the stressed 
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mice compared to the controls, implicating the BNST in both, social behaviour and stress 
reaction.  
 
From a more clinical perspective, changes in the BNST activation have been considered 
in human anti-social behaviours, like psychopathy (Lebow and Chen 2016). While both 
aggressive behaviours and impaired fear processing walk hand in hand with known roles 
of the BNST, no studies have actually been published that would link psychopathic 
tendencies with the BNST, other than indirectly by showing reduced amygdala activation 
(Marsh 2013). As will be discussed later in more detail, the BNST and amygdala do not 
always activate in synchrony, and therefore the role of the BNST cannot be extrapolated 
through the activation of the amygdala. As another example, human social anxiety is 
considered to be a disorder caused by dysfunctioning fear inhibition, social recognition, 
and motivation systems (Coria-Avila et al. 2014; Lebow and Chen 2016). In these 
behavioural systems, the BNST is seen again as an important information relay due its 
contacts with the frontal cortex, the fear-related amygdala, and the VTA, mediating the 
motivational aspects of the social encounters. Yet again, despite the hypothesised 
association, no studies showing BNST-related changes in patients diagnosed with any 
form of social anxiety disorders has been published.  
3.3.3 Anxiety disorders 
 
The rising interest in the BNST within the neuroscience community stems from the 
knowledge of the BNST activation during prolonged fear states (Lebow and Chen 2016). 
It has been known for decades – making it also an often-cited brain fact in non-scientific 
journalism –  that the amygdala is activated during the moments of fear in humans and in 
other mammals (Spevack et al. 1975). Later, evidence for crucial role of a set of brain 
regions connected to the amygdala (hence named the “extended amygdala”) on the fear-
related behaviours have been gathered (Davis et al. 2010). The BNST is a major part of 
the extended amygdala, and it is today known to be important in generating sustained fear 
states, or “anxiety,” distinct from phasic fear (referred here as “fear”) generated by the 
amygdala.    
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The difference between amygdala and the BNST has been shown by (Sullivan et al. 2004) 
in a test, where they lesioned the BNST and the CeA, and tested behavioural and 
physiological effects caused by different fear-conditioning paradigms. The lesions in the 
amygdala attenuated the freezing behaviour and the corticosterone responses in the cases 
of both the acute tone-conditioned and the context-conditioned fear stimuli. Meanwhile, 
the lesioning of the BNST did not have any effect on the responses to the tone, but 
disrupted the context-conditioned fear reaction. The same has been seen in a human study, 
where images of spiders were shown to patients with arachnophobia (Straube et al. 2007). 
The imagery alone caused activation in the BNST, as seen with fMRI, but not in the 
amygdala. In another, similar test, a live tarantula was brought to the same room with the 
non-phobic subjects: the closer the spider was brought to the person in the fMRI, the more 
activation in the BNST, but also in the amygdala, was observed (Mobbs et al. 2010). 
These data, together with evidence from many other studies, have been used to build a 
theory, where the BNST mediates the apprehension, and the anticipation of a distant threat, 
whereas both the BNST and the amygdala work together when the threat is immediate 
(Lebow and Chen 2013).  
 
As described earlier, the amygdala and the BNST together form a circuit, through which 
the modulation of the stress state, via the HPA axis, is conveyed (Dong and Swanson 
2004b). The idea is built upon the data showing CRF-expressing projections from the 
BNST to the amygdala activating the CRF-neurons in the CeA, which in turn activate the 
HPA axis  (Davis et al. 2010).  It is noteworthy, that BNST and amygdala are active parts 
of the homeostatic stress-circuitry, enabling the evolutionarily important “fight or flight” 
decision making and adaptation mechanisms with sequelae over generations. 
 
Results implicating the BNST with anxiety are also increasingly relevant in clinical 
respect, as studies have shown differences in the BNST functioning in patients with 
generalized anxiety disorder, when compared to healthy controls (Yassa et al. 2012; Buff 
et al. 2017). Chronic treatment with fluoxetine, a selective serotonin reuptake inhibitor 
used in the treatment of anxiety disorders, has been shown to reduce stress-induced 
expression of immediate early gene c-Fos in the rat BNST, indicating decreased 
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activation (Bechtholt et al. 2007). Together, these data make BNST an interesting target 
region for future research in pharmaceutical treatments of anxiety. 
 
Post-traumatic stress disorder, or PTSD, is a psychiatric condition characterized by 
sustained fear states following a traumatic event (Marshall and Garakani 2002). PTSD 
patients show changes in function of the HPA axis and the autonomous nervous system, 
and in cortisol levels, all of which are linked with the BNST. Animal models have 
implicated the BNST in PTSD-like chronic fear states, but no human study has shown 
any conclusive evidence on BNST dysfunction in PTSD patients (Etkin and Wager 2007; 
Bremner et al. 2008; Rodriguez-Sierra et al. 2016). Still, because of the known 
correlations between the BNST function and the observed PTSD dysfunctions, BNST-
downregulation as a potential future pharmacotherapeutic strategy for PTSD is increasing 
in interest (Marshall and Garakani 2002; Fink 2011).  
3.3.4 Addiction and withdrawal 
 
Drug addiction is a chronic, relapsing disorder defined by compulsive drug seeking and 
concurrent relapse to drug use (Koob 2008; Koob and Volkow 2010). It is also 
characterized by activation of the brains stress systems, often considered to be activated 
as an opponent process to the excessive activation of the brains reward system, and to 
maintain the homeostasis in the chronic presence of the drug of abuse. Stress is also a 
well-known trigger for relapse. As discussed before, the BNST is an important relay in 
the formation of the stress state, and it has been shown that the stress increases CRF 
signalling in the BNST, which then induces drug-seeking behaviours in cocaine-trained 
rats (Erb and Stewart 1999; Partridge et al. 2016). The CeA is most likely also an 
important part of this circuitry, as it is one of the main sources of the CRF signalling in 
the BNST, and several drugs have been shown to affect the neurons in the CeA  (Roberto 
et al. 2006; Chen et al. 2013). For example, Herman et al. (2013) showed that ethanol 
increases firing rates of CRF-neurons innervating the BNST.   
 
The BNST is not linked to addiction only through stress, but is known to modulate the 
brain reward system as well (Georges and Aston-Jones 2001; Jennings et al. 2013). Kim 
et al. (2013) showed that optogenetic activation of projections from what they dubbed the 
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anterodorsal BNST (including anteromedial, anterodorsal, and juxtacapsular nuclei, but 
not oval nucleus) to the VTA induced a place preference, indicating positive valence. In 
another study, Jennings et al (2013) optogenetically activated the GABAergic and 
glutamatergic projections from the ventral BNST to the VTA. The activation of the 
glutamatergic projection was aversive in nature, whereas the activation of the GABAergic 
projection showed rewarding properties. Similarly, the inhibition of the BNST-VTA 
projections cancels the place preference induced by ethanol  (Pina and Cunningham 2017).  
Rinker et al. (2017) linked the stress-induced CRF signalling in the BNST to the VTA by 
showing that the selective inhibition of the BNTS-VTA CRF-projections decreases binge 
like ethanol consumption in mice. The dopaminergic signalling works in the other 
direction as well, through the VTA projections to the anterior BNST: practically all of the 
drugs of abuse are known to increase dopamine signalling in the BNST, and the injection 
of dopamine receptor antagonist to the BNST is shown to decrease cocaine reinforcement  
(Epping-Jordan et al. 1998; Carboni et al. 2000; Meloni et al. 2006). 
 
Two studies have shown, that the noradrenergic signalling to the BNST is critical in opiate 
withdrawal (Aston-Jones et al. 1999; Delfs et al. 2000). The BNST activation was shown 
to be increased during the opiate withdrawal, indicated by increased immediate early gene 
c-Fos activation, which was reduced by β-adrenergic receptor antagonist propranolol, 
directly administered to the BNST. Also, lesioning the noradrenergic projections from 
the caudal medulla to the BNST attenuated the opiate-withdrawal-induced place aversion.  
 
The BNST has also been shown to go through adaptations and plastic changes in the 
presence of drugs of abuse (Korpi et al. 2015). For example, chronic administration of 
cocaine has been shown to increase the levels of plasticity related ΔFosB, and long-term 
administration of ethanol causes robust synaptic plasticity changes in the BNST  
(Weitlauf et al. 2004; Nunez et al. 2010). 
 
Some data gathered has also implicated the BNST in human addiction (Avery et al. 2016). 
Two fMRI studies have been carried out, one showing increases in BNST activity in 
response to smoking cues in nicotine-addicted participants, while the other showed 
increased functional connectivity between the BNST and the amygdala in alcohol use 
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disorder patients relative to healthy controls (Dagher et al. 2009; O'Daly et al. 2012) 
While certainly more human studies on the BNST’s role in addiction is needed, interest 
towards novel pharmacological interventions for addiction working through the BNST is 
rising (Avery et al. 2016). Some promising evidence has already emerged; a GABA 
superagonist gaboxadol shows aversive effects while activating neurons solely in the oval 
BNST, and is therefore hypothesized to be a potential anti-addictive drug (de Miguel et 
al. submitted). In summary, the BNST has been connected to several behavioural 
functions, some of which carry significant clinical implications (Table 3; Lebow and 
Chen 2016). From the clinical perspective, the data used as evidence have some caveats, 
like the small differences in structure and connectivity of the BNST between the humans 
and rodents that could, in the end, prove to be surprisingly significant, and the usage of 
the methodologically challenging fMRI in the human BNST studies, as discussed shortly 
before (Vul et al. 2009; Larsson et al. 2016). Still, despite these minor challenges, the 
growing evidence clearly suggest the BNST to be an important brain region in the control 
of behaviour, both in health and in several neuropsychiatric disorders. 
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Table 3. Some neuropsychiatric disorders in which the BNST has been implicated. DBS 
– deep brain stimulation; LTP – long-term potentiation; OCD – obsessive-compulsive 
disorder; PTSD – post-traumatic stress disorder.  
Disorder Implication of the BNST Reference 
Anxiety Chronic stressors decrease 
BNST LTP 
 
Optogenetic activation of 
BNST modulates anxiety-
responses 
 
Chronic psychosocial stress 
activates BNST 
 
Conrad and Winder 2010  
 
 
Kim et al. 2013  
 
 
 
Laine et al. 2017 
 
PTSD Increased BNST activity in 
PTSD-like rats 
 
Rodriguez-Sierra et al. 2016 
OCD DBS in BNST area alleviates 
symptoms 
 
Nuttin et al. 1999;  
Islam et al. 2015 
Phobias Increased BNST activation 
and enhanced amygdala-
BNST connectivity 
 
Münsterkötter et al. 2015  
Addiction Increased BNST activity in 
response to smoking-cues in 
nicotine dependent 
 
Bupropion, used in smoking 
cessation, increases 
catecholamine output in 
BNST 
 
Chronic cocaine increases 
BNST plasticity markers 
 
Dagher et al. 2009  
 
 
 
Cadeddu et al. 2014  
 
 
 
 
Nunez et al. 2010  
 
Depression Increased α-band oscillation 
in the BNST (relative to 
OCD patients) 
 
Antidepressants increase 
catecholamine output in the 
BNST 
 
BNST lesion blocks 
development of learned 
helplessness 
 
BNST lesion enhances 
development of learned 
helplessness  
Neumann et al. 2014 
 
 
Cadeddu et al. 2014  
 
 
 
Hammack et al. 2004 
 
 
 
Schulz and Canbeyli 2000  
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3.4 Somatostatin in the BNST 
 
In the rodent BNST, Sst-expression is highly concentrated in the oval nucleus, and in 
slightly lesser extent in the juxtacapsular, the anteromedial and the anterolateral nuclei 
(Magableh and Lundy 2014; Nguyen et al. 2016). Otherwise, Sst-neurons are sparsely 
expressed in the BNST structure, with another smaller cluster of Sst-neurons in the 
posterior BNST (Moga et al. 1989). Sst-immunoreactive neurites can be seen in every 
BNST nuclei, which is considered to be an indication of Sst-innervation. This is also 
reflected by the observed expression of Sstr1, 2 and 4 in the BNST (Patel 1999). The 
study by Magableh and Lundy (2014) shows, by retrograde neuronal tracing, that Sst-
neurons from the BNST innervate the PBN, together with CRF-projections from the same 
regions. In humans, as described earlier, Sst is largely concentrated in the central division 
of the BNST, where as many as 25 % of cell bodies are Sst-immunoreactive (Figure 5; 
Lesur et al. 1989; Walter et al. 1991). Sst-expression in the BNST can be considered 
intuitive because of the logical correlation between the proven anxiolytic properties of 
the Sst and the anxiety-related role of the BNST. Sst-signalling is known to be activated 
in response to stressors, and the activation of the Sstr-signalling has been shown to 
suppress CRF-induced stress responses(Shibasaki et al. 1988; Butler et al. 2012; Stengel 
and Tache 2017). Still, despite this evidence and the emergence of the modern genetic 
tools, like the transgenic animal models, optogenetics, and chemogenetics, no research 
on BNST Sst-neurons’ roles in behaviour has been published.   
 
Altogether, the BNST is known to be an important hub between the cortical and 
subcortical brain systems, mediating many stress- and affect-related responses (Calhoon 
and Tye 2015; Lebow and Chen 2016). Because of the vast expression of different 
receptors to target, and due to the rise of the neuron subtype-specific methods – like 
optogenetics and chemogenetics – to probe the characteristics of these receptor systems, 
the BNST is likely to become a target of pharmacological interventions in the future. The 
significance of the BNST in the control of homeostasis gives rise to some major 
difficulties in the drug development: for example, while the inhibition of the BNST might 
be able to reduce the symptoms in anxiety disorders, too broad inhibition of the site is 
very likely to cause severe HPA axis or autonomic nervous system related adverse effects. 
This is especially true because of the great abundance of CRF-neurons in the BNST, as it 
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is known that modulation of the CRF-system affects the HPA axis function  (Ambrogio 
et al. 2008). Similar effects are also known to be present in clinically used antipsychotic 
and antidepressant drugs (Bhagwagar et al. 2002; Cohrs et al. 2006). In this regard, the 
knowledge that the BNST harbours a significant cluster of Sst-neurons could be used to 
facilitate the drug discovery (Walter et al. 1991; Bota et al. 2012; Nguyen et al. 2016). 
Since the Sst-signalling has been shown to counteract the effects of the CRF, the 
activation of the BNST Sst-neurons could be used as an anxiolytic or anti-addictive 
treatment: for example, it has been shown that CRF-antagonism in the VTA reduces 
anxiety caused by cocaine administration (Ettenberg et al. 2015). Similar effect could be 
possible through pharmacological activation of the BNST Sst-neurons, which would 
inhibit the BNST-VTA CRF-projections. To achieve this kind of pharmacotherapy, the 
nature of the BNST Sst-neurons should be known in more depth, and their potential role 
in modulating behaviour on their own should be addressed by further research.  
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4 AIMS OF THE STUDY 
 
As reviewed, Sst is a widely expressed neuropeptide with implications in several brain 
functions, both in health and in disease. Importantly, Sst-system is considered to drive 
endogenous anxiolytic and stress-alleviating actions. Sst-neurons, on the other hand, are 
best known as interneurons in the cortex and hippocampus, but significant groups of Sst-
neurons are also harboured in the amygdala and BNST. Both are known to be involved 
in the brain circuits mediating fear- and anxiety-related behaviours, stress reactions, and 
to be involved in addiction. Even though the existence of these Sst-neurons in the oval, 
anterolateral and juxtacapsular BNST has been known for years, there has been very little 
published research on them (Moga et al. 1989; Bota et al. 2012; Magableh and Lundy 
2014). Anxiety disorders and addictions are a significant burden on society whereas the 
treatments of these disorders in still largely lacking. Finding a way to, for example, inhibit 
an overactive stress relay like the BNST in anxiety disorder patients would be a novel 
therapeutic strategy. To achieve this, more knowledge on the basic action of the 
neurocircuitry mediating the behaviours and reactions dysfunctioning in the 
neuropsychiatric disorders is needed.  
 
In this work, I studied the innervation profile of the Sst-neurons in the anterodorsal part 
of the BNST (adBNST; constituting of oval, juxtacapsular, anterolateral, and 
anteromedial BNST) by viral anterograde tracing to show whether the Sst-neurons are 
local interneurons or projection neurons.  
 
I also studied the role of the adBNST Sst-neurons in behaviours related to the BNST 
activation, particularly anxiety-, reward-, and drug withdrawal-related behaviours, with 
chemogenetics, utilising a set of designer receptors exclusively activated by designer 
drugs (DREADDs; Zhu and Roth 2015).  
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5 METHODS AND MATERIALS 
 
5.1 Experimental animals 
 
For the behavioural studies, a mouse line expressing Cre-recombinase enzyme in Sst- 
neurons (Ssttm2.1(cre)Zjh/J; Jackson Laboratories) was used. The tracing studies were done 
using a transgenic mouse line, acquired by breeding the Sst-cre mice with a reporter 
mouse line (B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J; Jackson Laboratories) resulting 
in a mouse line with tdTomato fluorescent reporter protein expressed together with Cre-
recombinase in Sst-neurons.  Male mice aged between 6 – 16 weeks, weighing 20 – 35 g 
at the beginning of the experiments, were group housed (2 – 4 mice per cage) in 
individually ventilated cages with 12-hour light cycle (lights on at 06.00 am), standard 
aspen bedding, nesting material and a plastic in-cage housing, with water and rodent chow 
available ad libitum.  
 
Originally, I tested both males with homozygote and heterozygote genotype on the 
somatostatin-cre mouse line for behavioural changes, but excluded the homozygote mice 
from the analysis as per emerged update from the animal provider, due to findings of 
abnormal Sst-RNA expression and behavioural phenotypes (unpublished data, Jackson 
Laboratories). All the animal tests were approved by the Provincial Government 
(permission ESAVI/3806/04.10.07/2015) and conducted in accordance with the national 
and university-level ethical and procedural guidelines. 
5.2 Virus constructs 
 
For the neural tracing study AAV2/8-Cag-Flex-Myr-eGFP (4x1012 genome copies/ml) 
construct was used, purchased from Neurophotonics Center (CERVO Brain Research 
Centre, Quebec, Canada). The viral vectors used in the DREADD-driven behavioural 
studies were built upon the following constructs: rAAV8/hSyn-DIO-hM3Dq-mCherry 
(5,9x1012 genome copies/ml) for the transfection of the Gq-coupled designer receptors, 
and rAAV8-hSyn-DIO-mCherry (6,4x1012 genome copies/ml) for the mCherry 
expressing controls, both obtained from University of North Carolina Vector Core.  
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5.3 Animal surgery and stereotaxic viral injections 
 
The mice were anesthetized with a mixture of isoflurane (4 % for induction, 0.5 – 2 % for 
maintenance) and oxygen (flow rate 0.8 – 1 l/min), after which they were placed into a 
stereotaxic frame (Kopf Instruments, Tujunga, CA, USA). Before the opening incision 
on the scalp, iodopovidone was applied on the surgical region, and lubricative eye gel 
applied to prevent corneal damage. Small craniotomies were made above the target 
regions and viruses were injected with a self-made steel cannula (30 Gauge) connected 
to a Microliter syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland) and a pump 
system (Univentor Ltd, Zeijtun, Malta). Stereotaxic coordinates, relative to bregma, AP 
+0.2 mm, ML ±1.0 mm DV -4.0 mm were used for BNST, chosen based on the the Mouse 
Brain Atlas (Franklin and Paxinos 2008) and verified with dye injections. For the tracing 
studies, a unilateral injection of 120 nl was made, whereas for the DREADD-delivery 
two, bilateral injections of 120 nl were made (Figure 6A). After the injection, the injector 
was first held at the injection spot for 5 minutes and then slowly withdrawn to avoid 
upward flow of the liquid. The mice were sutured with Ethicon Perma-Hand silk or 
PDS*II polydioxanon monofilament sutures. They were administered 1 mg/kg carprofen 
(s.c.) for postoperative analgesia, and were let to recover from anaesthesia in a 37 °C 
incubator until ambulatory. All the tests, behavioural and immunohistochemical, started 
2 weeks after the last viral injections to allow adequate receptor expression. 
 
Figure 6. Sst-neuron targeting of adBNST neurons. A. A schematic of the bilateral 
stereotaxic delivery of vectors encoding activating Gq-coupled designer receptor or 
mCherry protein as a control. B - C. Representative sections showing the case 
examples of successful bilateral transfection (B), and a unilateral transfection (C).  
aca – anterior commissure; adBNST – anterodorsal part of the BNST; lv – lateral 
ventricle. The scale bars indicate 500 µm.    
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5.4 Behavioural studies 
 
The mice were habituated to handling for two days prior to the first behavioural 
assessment. All tests were carried out in the morning time between 7.00 AM – 11.00 AM 
unless otherwise stated. For each behavioural test, the mice were brought to the adjacent 
room to habituate at least 1 h before the first test trial, and at least 30 min before clozapine-
N-oxide (CNO) pre-treatment (1 mg/kg, i.p.). The behaviour was recorded and analysed 
using the EthoVision software (Noldus Information Technologies, Leesburg, VA, USA).   
5.4.1 Elevated plus-maze  
 
For the assessment of anxiety-like behaviour the elevated plus-maze test was performed. 
The mice were placed in the centre of the maze (40 cm long arms, 40 cm above the 
ground), facing always the same closed arm, 30 min after the CNO injection and allowed 
to freely explore the maze for 5 min. Test was performed at the light intensity of 175 lx. 
The time spent in the open arms, head dips over the edge of the open arms, and 
exploratory stretching behaviour were measured. Open arm entries were interpreted as a 
behaviour where the mouse has entered the arm with all the four paws,  whereas the partial 
entries to the open arms, in which at least one of the paws remains in the centre area or in 
the closed arm, were interpreted as stretch-attend postures. Head dips and stretching 
behaviour were manually scored from the recorded video files. 
5.4.2 Open field and novel object exploration  
 
To further evaluate anxiety and exploratory activity, a two-phased open field test was 
performed. In the first phase, the mice were placed in the centre of an open arena field 
(50 x 50 cm) and were allowed to freely explore the arena for 3 min. A round plastic 
object (diameter 4 cm) was quickly placed in the centre of the arena and the mouse 
behaviour was then recorded for another 3 min (Vekovischeva et al. 2013). Testing was 
performed at the light intensity of 175 lx. For the analysis of the behaviour, the arena was 
divided into central and peripheral areas so that the 25 % of the total area in the centre 
dedicated as the centre. Time spent in the centre of the arena and the total distance moved 
were assessed through the whole 6 min trial, as well as separately for the first and the 
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second 3 min phase. Object related exploration was manually scored from the video 
record as contacts with the novel object. 
5.4.3 Conditioned place preference 
 
A biased place conditioning paradigm was used to assess the possible rewarding or 
aversive effect of the CNO-induced activation of BNST. The paradigm was built of three 
phases: in the first, the pre-conditioning phase, the mice were, for 15 min, presented with 
two distinct floor materials, a metal plate with 5 mm holes 3 mm apart, and a plastic grid 
with 2 cm wide bars 0.5 cm apart, placed in 1:1 relation covering the floor of each 
Plexiglass cage (19 x 36 cm). The pre-test was repeated three times and the time spent on 
the preferred floor material on the third test was used as a basis of the behavioural analysis. 
During the conditioning phase, the cage floor was covered solely with either of the two 
materials at the time. The daily routine consisted of two 30 min trials, one in the morning 
(between 7.00 – 11.00 AM) and one in the evening (between 4.00 – 7.00 PM). In the 
morning trial, the mice were injected with 10 ml/kg 0.9 % saline (i.p) 30 min prior to 
placing them on the preferred floor material. In the evening trial, the mice were injected 
with 1 mg/kg CNO (i.p.) 30 min prior to placing them in the cage with the non-preferred 
floor material. The daily conditioning routine was performed on four consecutive days. 
The post-conditioning assessment of the aversion was performed 48 h after the last 
conditioning trial. The mice were again placed in cages with 1:1 ratio of the two floor 
materials and the time spent on each material was assessed. The trial was repeated in a 
similar fashion the next day, but with 10 ml/kg 0.9 % saline injection 30 min prior the 
test. The difference in the time spent on the non-preferred floor material during the third 
pre-conditioning and the post-conditioning tests were used as the measure of reward or 
aversion (i.e. time-shift). 
5.4.4 Naltrexone-precipitated morphine withdrawal 
 
The mice were injected 10 ml/kg volume morphine (s.c.) twice daily, in the morning 
between 8 – 10 AM, and in the afternoon, between 5 – 6 PM, with the dose progressively 
increasing from 8 to 45 mg/kg over a period of 5 days (Figure 11A; Suzuki et al. 1996; 
Vashchinkina et al. 2017). In the fifth day, 2 h after the final morphine administration, 
the mice were injected with 1 mg/kg CNO (i.p.), and 30 min after the CNO the withdrawal 
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symptoms were precipitated by injecting 3 mg/kg naltrexone (s.c.). The mice were 
immediately after the naltrexone administration placed in transparent acrylic cylinders 
(30 cm height, 20 cm diameter), and the behaviour was recorded with a video recorder 
(Sony HDR-CX) for the following 30 min. The number of jumps, exploratory rearings, 
and forepaw tremors were manually scored with EthoGraph 2.06 software (Ritec, St. 
Petersburg, Russia). 
5.5 Immunohistochemistry and imaging 
 
To enhance the fluorescence signal for the neural tracing study, immunostaining was 
performed for the GFP protein. All the mice were anesthetized with pentobarbital (100 
mg/kg i.p.) and transcardialy perfused with first 1x PBS followed by 4 % PFA. The 
dissected brains were fixed in 4 % PFA at 4 °C for 12 hours, then transferred to 30 % 
sucrose in PBS until the brains were completely submerged, at least for 48 h. The brains 
were then frozen with isopentane and stored in -80 °C until sectioned. 80 µm coronal 
sections were cut throughout the brain with cryostat (CM3050S, Leica Biosystems, 
Wetzlar, Germany). For immunostaining, the sections were washed at room temperature 
in 1x PBS (5 min, 3 times), blocked with 1 % BSA with 0,3 % Triton X-100 in 1x PBS 
for 1 h at room temperature. The sections were then incubated with the primary antibody 
(chicken anti-GFP) overnight at 4 °C, washed with 1x PBS (5 min, 3 times) and incubated 
with secondary antibody (goat anti-chicken with Alexa Fluor 488) for 2 h at room 
temperature. Sections were then washed once more with 1x PBS (5 min, 3 times), 
mounted on slides, and coverslips were applied with FluoroSave mounting medium. 
Mounted sections were imaged with AxioImager epifluorescent microscope (20x Plan 
Apochromat dry immersion objective, numerical aperture NA 0.8; 40X EC Plan Neofluar 
dry immersion objective, NA 0.75; 100x EC Plan Neofluar oil immersion objective, NA 
1.3) and Axio Scan.Z1 slidescanner (20x Plan Apochromat dry immersion objective, NA 
0.8; both by Carl Zeiss AG, Oberhocken, Germany) for double-labelled fluorescent 
neurites as a marker for projections. 
 
To verify the correct localization of the DREADD-carrying vector injections, 
immunostaining was performed for the mCherry fluorescent protein using the same 
protocol described above, except for collecting 40 µm coronal sections and using primary 
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rabbit anti-mCherry and secondary goat anti-rabbit with Alexa Fluor 594 antibodies. The 
mounted sections were imaged with AxioImager epifluorescent microscope, and analysed 
to identify the locations of the transduced neurons. Only the animals with successful viral 
transduction localized at adBNST area were included in final data analysis. 
5.6 Drugs 
 
The clozapine-N-oxide (CNO; Carbosynth Ltd., Berkshire, UK) was dissolved in 
dimethyl sulphoxide (DMSO; 0.5 % of total volume) and diluted with 0.9 % saline. 
Morphine hydrochloride and naltrexone (both from Yliopiston Apteekki, Helsinki, 
Finland) were initially dissolved in, and diluted with 0.9 % saline. Carprofen (Norocarp 
vet 50mg/ml, Norbrook, Newry, UK) and pentobarbital (Mebunat vet 60 mg/ml, Orion 
Pharma OYj, Espoo, Finland) were diluted with 0.9 % saline. Isoflurane (Vetflurane 1000 
mg/g, Virbac S.A., Carros, France) was vaporized and mixed with oxygen with VetEquip 
(Livermore, CA, USA) isoflurane vaporizer.   
 
5.7 Antibodies 
 
For the DREADD verification immunohistochemistry, rabbit anti-mCherry (ab167435, 
Abcam, Cambridge, UK) was used as a primary antibody, diluted 1:800 in the blocking 
solution. As a secondary antibody, donkey anti-rabbit Alexa Fluor 594 (ab150076, 
Abcam) was used, diluted 1:1000 in the blocking solution. For the tracing fluorescent 
enhancement immunohistochemistry, chicken anti-GFP (ab13970, Abcam) was used as 
a primary antibody, and goat anti-chicken Alexa Fluor 488 (ab150169, Abcam) as a 
secondary antibody, both diluted 1:800 in the blocking solution. 
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5.8 Reagents and solutions 
 
The solutions and the reagents, apart from the drugs and antibodies, used in the study are 
presented below in the Table 4. 
 
Table 4. The reagents and solutions used in the study. 
Reagent Vendor 
10 x phosphate-buffered saline (PBS)  
1.3 M NaCl 
70 mM Na2HPO4 
30 mM NaH2PO4 
dH2O 
Fluka 
Fluka 
Fluka 
4 % Paraformaldehyde (PFA)  
Paraformaldehyde, 96 % 
1 x PBS 
Acros Organics 
University of Helsinki 
30 % Sucrose solution University of Helsinki 
Isopentane Fisher BioReagents 
Antifreeze solution  
25 % Glycerol 
25 % Ethylene glycol 
1 x PBS 
Fisher BioReagents 
Fisher BioReagents 
University of Helsinki 
Blocking solution  
1% Bovine Serum Albumin 
0.3 % Triton X-100 
1 x PBS 
Sigma Aldrich 
BDH Laboratory Supplies 
University of Helsinki 
FluoroSave Reagent Millipore 
Dimethyl sulphoxide (DMSO) Sigma Aldrich 
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5.9 Data analysis 
 
In the tracing and DREADD experiments, the verification of the fluorescence signal 
location was qualitatively analysed post hoc with Zen software (Carl Zeiss AG, 
Oberhocken, Germany). Following the verification of the DREADD-expression, the mice 
were grouped into bilateral (Figure 6B, n=8), and unilateral (Figure 6C, n=10) hM3Dq-
DREADD groups (later referred to as bilateral and unilateral group, respectively), 
whereas the mice with no visible DREADD expression despite the injection (n=3) were 
added to the control group (total n=23). Statistical analysis was conducted using SPSS 
software version 24 (IBM Analytics, Armonk, NY, USA), and all the graphs were 
generated by using Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA). 
Shapiro-Wilk’s test was used to test for the normality of the data. For the analysis of the 
behavioural data, the comparisons across more than two groups were made by using a 
standard one-way analysis of variance (ANOVA). Differences between the populations 
were considered to be significant at P values below 0.05. All the data described and shown 
are presented as mean ± 95 % CI, unless otherwise stated.   
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6 RESULTS 
 
6.1 Anterograde tracing of the adBNST Sst-neuron outputs  
 
To study the efferents of the adBNST Sst-neurons, I unilaterally expressed Cre-inducible 
green fluorescent protein (GFP) in the adBNST of Sst-Cre-tdTomato reporter line mice 
(n=2). The adBNST showed fluorescent neurites (Figure 7A) and double-labelled neuron 
somas (Figure 7B) in the injection site, and robust local innervation all around the BNST. 
Interestingly, neurites visibly expressing both the native tdTomato-fluorescence, and the 
GFP-fluorescence from the injection were only visible near the injection site (not shown), 
but not further away in the proclaimed projection sites.  
 
A brainwide screening for GFP-labelled neurites revealed a robust innervation in the MeA 
(Figure 7D), and in slightly lesser extent in the CeA, to which the projections followed 
the stria terminalis (Figure 8A), and through the so called ventral amygdaloid pathway, 
or ansa peduncularis, proceeding through the lateral hypothalamus (LH), near the 
interstitial nucleus of the posterior limb of the anterior commissure (IPAC), and the 
substantia innominata (Larriva-Sahd 2004). Interestingly, there were no visible 
fluorescent neurites in the basolateral amygdala (BLA; Figure 7D), and only very few in 
the highly Sst enriched area of the medial part of the CeA (Figures 7D and 8A). 
Fluorescent neurites were also observable in higher abundance in the lateral 
hypothalamus (LH; Figures 7D and 8B). Anterior to the BNST, fluorescent neurites were 
seen to proceed towards NAc and ventral pallidum (VP; Figure 7C), but only a few 
fluorescent neurites were visible in NAc more anterior, at the level of frontal cortex. No 
innervation was visible in the VTA, or in the substantia nigra, but fluorescent neurites 
were observable in the lateral PAG (not shown), and in the PBN (Figure 7E). The tracing 
revealed that the projections are ipsilateral, as no neurites were seen on the contralateral 
hemisphere. No identifiable endpoints for the projections, like perisomatic baskets, were 
observable (Dabrowska et al. 2016). All the findings described were consistently 
observed in every screened mouse. Taken together, the adBNST Sst-neurons innervate 
both the local BNST network, and other brain areas (Figure 8C). 
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Figure 7. Anterograde neuronal tracer injected into adBNST reveals Sst-neurons 
projecting to stress-mediating brain regions. A. Green fluorescent neurons on the 
injection site are most prominent in the subnuclei rich in Sst, oval (ov) and 
juxtacapsular (ju) nuclei, but also visible in the anteromedial and anterolateral nuclei. 
B. In the BNST, neuron somas expressing GFP-fluorescence from the tracer as well 
as the tdTomato-fluorescence of the Sst-neurons of the reporter mouse line. C. 
Anterior to the injection site, GFP-fluorescent neurites are observable in moderate 
density in the ventral pallidum (VP) and in the nucleus accumbens (NAc). D. The 
most abundant expression of GFP-fluorescent neurites is observed in the medial 
amygdala (MeA), the medial part of the central nucleus of the amygdala (CeA), and 
in the lateral hypothalamus (LH). Neurites are virtually not present in the basolateral 
amygdala (BLA). E. The tracing also strengthened the data from previous research 
showing BNST Sst-neurons projecting to parabrachial nucleus (PBN), as fluorescent 
neurites were visible both in the medial (MPBN) and the lateral PBN (LPBN). dTom 
– native tdTomato-fluorescence from the Sst-neurons of the reporter mouse; GFP – 
GFP-fluorescence from the injected tracer; aca – anterior commissure; scp – superior 
cerebellar penduncule. The scale bar denoted 500 µm. 
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Figure 8. The adBNST Sst-projections follow known BNST output bundles. A. A set 
of GFP-fluorescent neurites followed the stria terminalis (st) to the amygdala. B. GFP-
fluorescent neurites were densely observable in the hypothalamic areas (here anterior 
hypothalamic nucleus (AHA) and posterior lateral hypothalamus (PLH), and, in part, 
ending up to the amygdala, very closely following the ventral amygdaloid pathway, 
or the ansa peduncularis, going around the internal capsule. C. Schematic 
representation of the major observed output areas of the adBNST Sst-neurons. NAc – 
nucleus accumbens core; VP -  ventral pallidum; LH – lateral hypothalamus; MeA – 
medial amygdala; PAG – periaqueductal gray; PBN – parabrachial nucleus. dTom – 
native tdTomato-fluorescence from the Sst-neurons of the reporter mouse; GFP – 
GFP-fluorescence from the injected tracer. The scale bar denotes 500 µm. 
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6.2 Anxiety-like behaviour after specific activation of the adBNST Sst-neurons  
 
To study how the selective activation of the adBNST Sst-neurons affects acute anxiety-
like behaviour, the mice were pre-treated with CNO (1.0 mg/kg i.p.) and, 30 min later, 
were tested with elevated-plus maze and open field paradigms (Figure 9A). In the 
elevated-plus maze, the CNO-induced activation of the Sst-neurons did not have any 
effect on the movement of the mice in the different groups (Figure 9B; F(2,38)=0.364, 
p=0.139, 95%CI [17.13 – 23.22]). At the same time, it did not seem to have any 
significant effect on the time the mice spent in the open arms (Figure 9C; F(2,38)=1.15, 
p=0.327 95%CI [43.39 – 62.49]), nor in the exploratory activities, like the frequency of 
the stretch-attend postures (Figure 9D; F(2,38)=0.276, p=0.191, 95%CI [10.28 – 13.48]) 
or the head dips (Figure 9E; F(2,38)=1.930, p=0.159, 95%CI [13.43 – 21.88]).  
 
In line with the above results, no effect by CNO on the movement between the groups 
was observed in the open field test (Figure 9F; F(2,38)=1.782, p=0.183, 95%CI [34.53 – 
38.81]). Similarly, no differences in anxiety-related behaviours, like in the time spent in 
the centre of the arena (Figure 9G-I; total F(2,38)=0.658, p=0.534, 95%CI [45.74 – 59.70]; 
first 3 min F(2,38)=0.142, p=0.524, 95%CI [22.05 – 28.89]; last 3 min F(2,38)=1.53, 
p=0.229, 95%CI [20.24 – 28.31]) or in the number of contacts with the novel object 
during the last phase of the test (Figure 9J; F(2,38)=0.339, p=0.715, 95%CI [0.75 – 6.42]), 
were observed. Altogether, the two used behavioural paradigms failed to demonstrate 
anxiety-related effects of the CNO-induced activation of the adBNST Sst-neurons.
   
45 
 
 
Figure 9. CNO-induced activation of adBNST Sst-neurons did not show effects on 
anxiety-like behaviour. A. The Gq-mediated activation of the Sst-neurons was induced 
with 1 mg/kg CNO i.p. 30 min prior the behavioural testing. Elevated-plus maze did not 
show statistically significant differences between the groups in movement (B), or in time 
spent in open arms of the maze (C), nor in exploratory behaviours, stretches (D) or head 
dips (E). Open field with novel object exploration showed no statistically significant 
differences in movement (F), nor in anxiety-related parameters like time in spent in the 
centre of the arena in different time frames (G-I.) or the number of contacts made with 
the novel object (J). All data presented as mean ± 95 % CI. 
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6.3 Reward-related behaviours after specific activation of the adBNST Sst-neurons 
 
I used a biased conditioned place preference test (CPP) to study the potential role of the 
adBNST Sst-neurons in rewarding behaviours. Locomotor activities during the 
conditioning trials were similar between the groups, with an exception in form of an 
observable difference during the 4th vehicle conditioning trial between the bilateral and 
control groups (Figure 10A, vehicle-DREADD F(2, 114)=4.15, p=0.0234) CNO-
DREADD F(2,114)=2.19, p=0.1257). The CPP test failed to show any statistically 
significant rewarding or aversive properties of CNO-induced activation of the adBNST 
Sst-neurons (Figures 10B and C, time-shift F(2,38)=0,580, p=0,565 95%CI [-22.953 – 
39.123]; time-shift with saline injection F(2,38)=1,080, p=0.350, 95%CI [-19.516 – 
68.269]). Taken together, the CNO-induced activation of the adBNST Sst-neurons did 
not impact place conditioning. 
6.4 Withdrawal symptoms after specific activation of the adBNST Sst-neurons 
 
To elicit the adBNST Sst-neurons’ role in giving rise to withdrawal symptoms, I used a 
method to precipitate the withdrawal symptoms with naltrexone in subchronically 
morphine-treated mice (Suzuki et al. 1996; Vandergriff and Rasmussen 1999). All the 
mice showed the predetermined symptoms, but the test failed to show any differences 
between the study groups in the number of jumps (Figure 11B, F(2,14)=1.158, p=0.343, 
95%CI [27.41 – 44.71]), rearings (Figure 11C, F(2,14)=0.009, p=0.991, 95%CI [25.12 – 
41.23]), or front paw tremors (Figure 11D, F(2,14)=0.09, p=0.914, 95%CI [142.56 – 
216.74]), nor in the total duration of the tremors (Figures 11E and F(2,14)=0.495, p=0.620, 
95%CI [24.92 – 27.22]). Altogether, the test here failed to demonstrate any morphine 
withdrawal-related effects of the CNO-induced activation of the adBNST Sst-neurons. 
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Figure 10. CNO-induced activation of the adBNST Sst-neurons showed no place 
conditioning effects. A. Changes in the locomotor activity between the groups during 
the conditioning were observed with a significant difference on the day 4 vehicle 
conditioning between the control and the bilateral group. B-C. Time-shift was 
measured as the difference in time the mice spent on the non-preferred floor material 
on the post-conditioning tests and the third pre-conditioning test. The test failed to 
show any significant differences between the groups without (B) or with a 0.9 % saline 
injection 30 min prior to the testing (C). All data presented as mean ± 95 % CI. 
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Figure 11. CNO-induced activation of adBNST Sst-neurons failed to show effects on 
morphine withdrawal symptoms precipitated by naltrexone. A. The mice were 
subchronicaly treated with increasing doses of morphine (8 to 45 mg/kg s.c. twice a 
day) during 4 consecutive days. On the day 5 the mice received 45 mg/kg morphine 
s.c,.followed by 1 mg/kg CNO-induced activation of the Sst-neurons, and 30 min after 
that 3 mg/kg naltrexone to precipitate the withdrawal symptoms. B-E. There were no 
significant differences in withdrawal symptoms scored during the 30 min following 
naltrexone administration. All data presented as mean ± 95 % CI. 
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7 DISCUSSION 
 
Neuropsychiatric disorders cause enormous social harm and financial loss worldwide  
(DiLuca and Olesen 2014). Still, only very few new therapeutics have emerged during 
the past years, and one of the main reason causing this is our lacking knowledge about 
the aetiology the disorders (Nutt and Goodwin 2011; Kesselheim et al. 2015). In the light 
of this problem, research on neuronal circuits behind the disrupted behaviours is an 
important approach towards the goal of finding new potential drug targets and therapeutic 
strategies  (Song and Knöpfel 2015; Hempel et al. 2017). The BNST has been shown to 
be an important part in the brain circuit active in anxiety and addiction, whereas the 
endogenous Sst-system has been shown to work in anxiolytic fashion (Lebow and Chen 
2016; Stengel and Tache 2017). Therefore, learning how the Sst-neuron population works 
in the BNST could prove to be very beneficial, for example, if it would be possible to 
activate the Sst-system to inhibit the overactive BNST to alleviate anxiety- and addiction-
related symptoms. To this end, the aim of this study was to characterise the Sst-neuron 
population in the anterodorsal parts of the BNST, and to probe their role in the 
neuropsychiatrycally relevant behavioural models.  
7.1 The adBNST Sst-neuron projections 
 
First, to demonstrate, whether the Sst-neurons are projecting neurons, I used a cell-type 
specific neuronal tracing technique with Sst-neuron reporter mouse line. I was able to 
demonstrate that the adBNST Sst-neurons can be considered as a projection neuron 
population. To the best of my knowledge, this is the first study describing projection sites 
of the BNST Sst-neurons. 
 
The projections were observed in brain regions known to control motivational states (NAc, 
VP), stress-related and defensive behaviours (MeA, CeA, LH, PAG), social behaviours 
(MeA, PAG), and autonomic and homeostatic regulation (LH, PBN). In much lesser 
extent, projections were also seen in the frontal cortex, and in the midbrain structures like 
the VTA, and substantia nigra. From the projections shown here, the BNST-PBN 
connection via Sst-neurons had been shown before by several studies, and can be 
therefore considered to be already confirmed (Moga et al. 1989; Magableh and Lundy 
50 
 
2014). The observed projection areas are all known to be output regions of the BNST, 
and reflect well the role of the structure in stress-control and valence monitoring (Lebow 
and Chen 2016). More precisely, the results of the present study suggest that the adBNST 
Sst-neurons could participate in modifying social behaviours and social stress through its 
projection to the CeA, MeA, and PAG, in modification of the reward system through the 
NAc, and VP, and in controlling homeostatic state – most likely in response to a presence 
of a stressor – through the LH, and PBN. In addition to these projections, fluorescent 
neurites of the adBNST Sst-neurons were observed widely in the BNST subnuclei, 
indicating at least some level of local innervation.  
 
One limitation to this tracing study, and the main reason limiting the definitive concluding 
of the projection sites, is the one-way character of the tracing. The viral construct used in 
the study was an anterograde tracer, designed to move from the somatodendritic site 
towards the axon (Chamberlin et al. 1998). Since definitive markers of innervation site, 
like perisomatic baskets, were not observed, it is impossible to say in most of the cases, 
if the neurites observed are innervating the area or only moving through the region to 
innervate another (Dabrowska et al. 2016). This is especially true in the LH, through 
which several well-known nerve fibre bundles, like the medial forebrain bundle, are 
known to project (Chi and Flynn 1971; You et al. 2001). This question could be clarified 
by using sagittal and horizontal sections in addition to coronal slices; this could make it 
possible to see the endpoints of the neuronal bundles. Another way to address the problem 
would be with a combination of anterograde and retrograde tracers, infusing the here 
described projection sites, discovered through anterograde tracing, with the retrogradely 
moving tracer and seeing if the fluorescent marker can be seen together with Sst-marker 
in the BNST (Tomioka et al. 2005; Kim et al. 2013). This would also enable better 
subregion-level spatial resolution, as here the spread of the injected virus causes neurons 
from several BNST nuclei to be transfected. Because of this, it is not possible to 
differentiate the output regions between their projection origins in this study.  
 
The above-mentioned double-labelling is another caveat in this study, because the co-
labelling of Sst-tdTomato and GFP of the tracer was observed only in the injection site 
somas (Figure 7B), and in only a few neurites very near the BNST. The projection sites 
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postulated in this work are therefore based only on the qualitative assessment of the 
presence of the GFP-fluorescent neurites. Firstly, to more certainly demonstrate the co-
localisation of the two fluorescent proteins, a quantitative method should be used  
(Pompey et al. 2013). The reason for the second problem, the lack of robust visible co-
localisation, is not known, but tdTomato not being expressed in, or not being transported 
from the soma to the distal branches of the axon, was hypothesized. Even though there 
are known caveats in mouse reporter lines in general, there is no published evidence to 
back up the theory, which is also contradictory with the fact that rather robust neurite 
bundles are visibly expressing tdTomato in several brain regions (Figures 7E and 8A;  
Chen et al. 2015). Therefore, a problem of more technical nature is more likely, and this 
way, probably solvable by repeating the study. 
 
A way of estimating the possibility of the Sst-innervation in the postulated projection 
areas is by looking at the known expressions of the Sst-receptors these regions, 
considering the prevalence of the receptor as an indicator of Sst-signalling at the site. 
Both the BNST and the amygdala are well known to have wide expression of several 
subtypes of Sstr: the potential projection sites in mind, both the CeA and MeA have been 
shown to express Sstr subtypes 1, 2, 3, and 4 (Table 1; Patel 1999; Stengel et al. 2012; 
Theodoropoulou and Stalla 2013) The wide expression of receptors is also true to the 
hypothalamus, PAG, and PBN, all expressing mostly Sstr1 and Sstr3, but not Sstr2. From 
the observed sites with fluorescent fibres, only the VP and the NAc are known to be sparse 
in Sstr expression. Of course, the expression of Sstr has only instrumental value in 
estimating whether a brain area is an output region of the Sst-neurons. Still, the minor 
expression of Sstr in the NAc and VP, together with the observation made in this study 
showing that the presence of GFP-positive fibres in the anterior regions of the NAc and  
VP are sparse, and that the both brain regions are at least partly in the ansa peduncularis, 
it is possible that these two areas are not actual output regions for the adBNST Sst-neurons 
(Larriva-Sahd 2004; Larriva-Sahd 2006). Meanwhile the other postulated projection areas, 
including the BNTS nuclei, are known to express Sstr, and therefore are quite possibly 
true projection sites for the adBNST Sst-neurons. Further studies are still needed to 
confirm this. 
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7.2 Behavioural effects of the adBNST Sst-neuron activation 
 
In order to elucidate the role of the adBNST Sst-neurons in the control of behaviour, I ran 
a set of behavioural tests combined with DREADD-mediated activation of the Sst-
neurons. The tests were originally chosen, before the tracing study, on the basis of the 
best known BNST-mediated behaviours displayed by the earlier studies: the BNST is 
known to elicit robust changes in anxiety-like behaviours, and therefore the EPM and OF 
tests were included; the BNST-VTA projections have been shown to affect reward-
associated behaviour, and this was tested by the CPP test; and noradrenergic signalling in 
the BNST is known to be important in the opioid withdrawal, which led into including 
the naltrexone-precipitated morphine withdrawal test (Aston-Jones et al. 1999b; Delfs et 
al. 2000; Jennings et al. 2013; Kim et al. 2013; Mazzone et al. 2016). 
 
The anxiety tests, EPM and OF, failed to show any anxiogenic or anxiolytic effects 
following the DREADD-mediated activation of the adBNST Sst-neurons (Figure 9). 
Several studies have shown very robust changes in the anxiety-like behaviours after the 
activation of the BNST: for example, the DREADD-induced activation of GABA-
neurons in the BNST was shown to significantly reduce the time the mice spend in the 
open arms in the EPM test (Mazzone et al. 2016). On the other hand, Kim et al (2013) 
showed that the optogenetic activation of the oval BNST neurons caused anxiogenic 
effects, while the activation of the anteromedial and the anterolateral BNST caused 
anxiolytic effects. This in mind, it should be noted that the spread of the DREADD-
expression is wide enough to involve several BNST subnuclei: the most abundant Sst-
expression is observed in the oval BNST, but Sst-neurons are also found in the 
anteromedial and anterolateral BNST (Figure 7A; Moga et al. 1989). Therefore, it is 
possible that the simultaneous activation of the Sst-neurons in the different subnuclei 
causes the activation of opposing neuronal pathways, leading to the situation with no 
behavioural phenotype. This problem could be tackled with optogenetics. Even if the 
DREADD-system has several strengths over the optogenetics, like that it does not depend 
on head-mounted devices possibly altering the animal behaviour on its own, optogenetics 
can potentially offer better spatial precision. This is due to the need to place the light-
source – needed for the modulation of the genetically expressed ion channels – to the 
brain region of interest in addition to the receptor gene expression itself, whereas the 
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pharmacological modulation of the DREADD-system affects all the transfected cells 
despite the localisation (Deisseroth et al. 2006; Aravanis et al. 2007; Zhu and Roth 2015). 
Similar balancing-out effect could stem from the co-expression of Sst and CRF, which 
has been shown to occur in the oval BNST (de Miguel et al. submitted). Sst is commonly 
considered to suppress the CRF-mediated stress signalling, and if the DREADD-induced 
activation was enough to activate the both signalling pathways, their countering effects 
could again lead to the lack of anxiety phenotype in EPM and OF (Shibasaki et al. 1988; 
Stengel and Tache 2017).  
 
Reflecting the results of the tracing studies done here, other kinds of anxiety-related 
endpoints could also be considered. The adBNST Sst-neurons were shown to send robust 
projections to the MeA, which is known to be a part of the social behaviour network 
(Figure 7D; Newman 1999, Goodson and Kabelik 2009). Because of this, anxiety tests 
incorporating social interaction or a predator simulation could show changes in the 
behaviour better than the approach-avoidance based tests used in this study (Calhoon and 
Tye 2015). Indeed, it has been shown that the exposure to predator ferret odour increases 
c-Fos activation of the Sst-neurons in the rat MeA (Butler et al. 2012). Contradicting the 
presented hypothesis, the same study showed increased c-Fos activation also in response 
to EPM test. Also, because the adBNST Sst-neurons were shown to send projections to 
homeostasis controlling brain regions, hypothalamus and PBN, changes in vital signs like 
the heart rate and breathing could be measured, as they are also known to be effected as 
a reaction to a stressor. 
 
Similarly to the anxiety tests, the CPP test failed to show any rewarding or aversive effects 
in response to the DREADD-induced activation of the adBNST Sst-neurons (Figure 10). 
If we consider the lack of anxiety-related behavioural phenotypes to be caused by the 
intrinsic properties of the Sst-neurons and not by any technical problem, this finding could 
be seen to be in line with previous data showing that the activation of the BNST signalling 
pathways that cause increase in the anxiety levels, also cause place aversion, and that the 
anxiolytic pathways are linked with place preference (Kim et al. 2013; Mazzone et al. 
2016). Since the adBNST Sst-neuron activation did not elicit changes in anxiety-related 
behaviours, it could be considered that the lack of observable effect on reward-related 
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behaviours is also presumable. The problem with this explanation is that the BNST- and 
the amygdala-associated reward behaviours are almost always somehow linked to the 
midbrain dopamine system, and the tracing study showed virtually no input from the 
adBNST Sst-neurons to the VTA or substantia nigra. Especially the lack of input to the 
VTA could be seen as an explanation for not observing rewarding or aversive behaviours 
in the CPP. The adBNST Sst-neurons were, on the other hand, shown to project to other 
reward-related brain areas like the NAc, VP, and PAG, which could affect the reward 
behaviour (Figure 7C). Yet, if the earlier prediction that the NAc and VP are not real 
projection sites for the Sst-neuron population is true, the lack of sufficient input to the 
reward-associated brain areas could explain also the absence of reward-related 
behavioural phenotypes in the CPP test. 
 
Also, the naltrexone-precipitated morphine withdrawal test failed to show any changes in 
the measured withdrawal symptoms (Figure 11). Noradrenergic signalling from the 
medulla and locus coeruleus to the BNST has been implicated in opiate withdrawal, and 
noradrenaline is considered to activate the BNST CRF-signalling (Aston-Jones et al. 1999; 
Delfs et al. 2000; Silberman and Winder 2013). Even if the ventral BNST is most often 
linked with the opiate withdrawal, the oval BNST, subregion with most abundant 
expression of Sst-neurons, is known to have significant expression of adrenergic receptors, 
indicating noradrenergic innervation (Delfs et al. 2000; Bota et al. 2012). Since the Sst-
signalling has been shown to counteract the effects of CRF, the activation of the adBNST 
Sst-neurons was hypothesised to attenuate the withdrawal symptoms (Shibasaki et al 
1988; Stengel and Tache 2017). The lack of observable differences in naltrexone-
precipitated morphine withdrawal-induced somatic symptoms could be explained by 
circuitry differences: two studies have shown that modulation of noradrenaline signalling 
in the BNST causes robust changes in withdrawal-related behaviours, intra-BNST β-
adrenergic antagonist infusion attenuating the place aversion, but not the somatic 
withdrawal signs of morphine withdrawal (Aston-Jones et al. 1999; Delfs et al. 2000). 
This has led to the assumption that the BNST is relaying the affective component of the 
withdrawal symptoms, but not the somatic components, which would be in line with the 
results of this study.  
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The common characteristics of the neuropeptides that are secreted as signalling molecules, 
such as Sst, could in part explain the lack of observation in all the behavioural paradigms 
used in this test. As noted before, the release of Sst is slower than that of classical 
neurotransmitters, and its effect lasts longer  (Baraban and Tallent 2004). Because of this, 
the role of the Sst-neurons could be more of a fine tuner than that of robust controller, 
like in the described example of the claustrum Sst-neurons, in which the Sst conveyed the 
changes in the action potential duration, while the inhibitory post-synaptic currents were 
mediated by GABA (Tang and Augustine 2015). This could mean that the activation of 
the adBNST Sst-neurons alone is not enough to produce robust behavioural changes, 
explaining the results of the behavioural test in this study. However, this explanation does 
not fully consider the known variety in the co-expression of Sst and other transmitters 
and neuropeptides. In many brain region, Sst is known to most often co-express GABA, 
and the modulation of the BNST GABAergic neurons has been shown to cause 
behavioural changes: Mazzone et al. (2016) were able to show robust decreases in open-
arm entries in EPM test and in the time spent in light in the light-dark box test in response 
to hM3Dq-DREADD activation of the BNST GABA neurons by using vesicular GABA 
transporter VGAT-cre mice. This does not necessarily contradict the idea of the fine-
tuning nature, as the adBNST Sst-neurons could be too small a population of neurons that 
the effect of their classic transmitter release might not be enough to cause changes in 
behavioural phenotype. The tests were done with healthy mice with no preliminary 
treatments of challenges, which could also affect the results, as it is known that not all the 
inhibitory or activating methods cause behavioural changes in otherwise untreated 
animals; for example, the DREADD-mediated inhibition of the BNST GABA-neurons 
alone was shown not to cause any observable anxiety-related behavioural changes 
(Mazzone et al. 2016). Preliminary stressor, like forced swimming or movement 
restriction, before the anxiety tests could cause symptoms that the activation of the 
adBNST Sst-neurons could alleviate. Also, inhibition of the neuron population, instead 
of activation, could yield different results.   
 
Related to the transmitter arguments, it should be noted that no wider histological 
characterisation of the adBNST Sst-neurons was done, and therefore no knowledge of 
their neurotransmitter profile is available. Also, there is no certainty that the DREADD-
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induced activation of the neurons is causing release of Sst. The DREADDs are inherently 
G-protein coupled receptors which cause more long-lasting effects through a variety of 
intracellular signalling pathways, as opposed to fast and rather robust effects of the ion 
channels (Armbruster et al. 2007; Alexander et al. 2009). Because the neuropeptides are 
known to need repeated, high frequency stimulation in order to be released, the G-protein 
coupled activation might not be enough. This question could be addressed with, for 
example, ex vivo electrophysiological measurements. Also, with the presented data it is 
not clear if the DREADDs activated the neurons at all. The lack of intended Sst-neuron 
activation would certainly explain the absence of the behavioural phenotypes. The 
functionality of the DREADD-system (both, the used vectors, and the activating ligand) 
could be tested with electrophysiology, or by finding out if the CNO administration 
causes changes in c-Fos expression in the transfected area compared to the sham control. 
 
DREADDs carry some methodological caveats, in addition to the ones already touched 
upon, that should be also considered when interpreting the behavioural data. As 
mentioned, DREADDs work through the G-protein coupled systems (Armbruster et al. 
2007; Alexander et al. 2009). Even if the expression of the designer receptor itself is a 
result of the use of genetic tools, the intracellular signalling molecules are of endogenous 
origin and the activation of the DREADDs might in the end have other, even longer 
lasting effects than the modulation of the neurons firing rate. Possibly relating to this, 
some groups utilising this chemogenetic technique have reported observable in vivo 
compensatory effects to take place as a response to the DREADD-induced modulations 
(Klapoetke et al. 2014; Saloman et al. 2016). For example, Saloman and colleagues 
discovered that the expression of inhibitory hM4Di-DREADD receptors in sensory 
neurons caused changes in Ca2+ and Na+ currents even in the absence of the ligand CNO. 
Also, very recently, some discrepancy concerning the role and the nature of the most 
widely used DREADD-ligand, CNO, has surfaced: Gomez et al. (2017) claimed that it is 
not CNO, but clozapine, product of in-system conversion of CNO, that causes the 
activation of the DREADDs. While conversion of CNO back into clozapine has not been 
shown to happen in mice, the conversion would have implications not only to the method 
itself, but also more acutely to this study because clozapine has been shown to have direct 
effects on Sst-expression (Salin et al. 1990; Arif et al. 2006).              
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10 CONCLUSIONS 
 
This study revealed that the Sst-neurons in the adBNST send projections outside the 
BNST nuclei, to several brain regions known to control fear and anxiety behaviours, as 
well as stress responses, and homeostatic balance. While the nature of the neuronal tracing 
method used in this study requires further research to confirm the observations made here, 
the postulated projection areas are well in line with the earlier research conducted on the 
connectivity of the BNST, and reflect the known functional and behavioural roles of the 
region. 
 
The behavioural research conducted in this study failed to reveal any significant 
behavioural effects for the activation of the adBNST Sst-neurons. These tests were the 
first ones performed to characterize the functional properties and behavioural role of the 
adBNST Sst-neurons, conducted in healthy animals, with no prior challenge or treatment, 
and are therefore not to be interpreted as a failure. While some methodological caveats 
could contribute to the result, and could be addressed with more accurate and site-specific 
technologies, in a wider perspective more thorough characterization of the adBNST Sst-
neuron population is needed to uncover its functions in the healthy brain. This is required 
to seek novel strategies to modulate this one – or any – neuron subpopulation, and to 
consider it as a future drug target in anxiety- and addiction related disorders.   
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